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Abstract 
Association of individual and combined metabolic risk factors with cancer  
Ruchi Bhandari, M.P.A., M.B.A. 
 
Introduction: The prevalence of metabolic risk factors (MRFs), individually and in the 
aggregate, is growing rapidly. There is limited biologic and epidemiologic evidence indicating an 
association between MRFs and cancer. The goal of this dissertation was to examine the 
association between individual and combined MRFs with subsequent risk of overall and site-
specific cancers of the breast, digestive system, and lung.  
Methods: A systematic review with meta-analysis on the association between metabolic 
syndrome (a cluster of MRFs) and breast cancer was conducted. In addition, associations 
between MRFs and risk of overall and site-specific cancers were assessed by multivariable Cox 
proportional hazards regression models. Lastly, associations between MRFs and age at cancer 
onset were examined by multiple linear regression analyses, using the general linear model. Data 
were derived from the NHANES I Epidemiologic Follow-up Study, and comprised participants 
ages 25 to 74 years at baseline. The primary metabolic risk factors were obesity (measured by 
BMI), high blood pressure, high total serum cholesterol, and diabetes. Analyses were adjusted 
for age, race, education, family income, physical activity, smoking status, and family history of 
cancer, and stratified by age and gender. All analyses incorporated the complex sample design 
and sample weights to produce national estimates. 
Results: Results from the meta-analysis show that metabolic syndrome was modestly associated 
with an increased risk for breast cancer in adult women. Findings from the study on the 
association between individual and combined MRFs and cancer risk suggest that diabetes 
independently, and presence of a combination of MRFs, may serve as markers for 
postmenopausal breast cancer risk. The association between diabetes and a combination of three 
or four MRFs and earlier age at onset was observed not only for postmenopausal breast cancer, 
but also for overall cancer in women 50 and older, digestive cancer in women, and lung cancer in 
males. 
Conclusion: Future research needs to examine this association between MRFs and site-specific 
cancers using specific, objective metabolic markers. The positive association of MRFs with 
postmenopausal breast cancer points toward the need to develop public health strategies to 
manage these risk factors. 
Keywords: Metabolic syndrome, metabolic risk factors, cancer, meta-analysis, breast cancer 
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CHAPTER 1.  INTRODUCTION 
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1.1 Introduction 
 Cancer, the "plague of our generation,"
1
 will have been diagnosed in 1.7 million men and 
women in the US in 2013.
2
 Accounting for one in four deaths, cancer is the second most 
common cause of death in the United States (US) after heart disease.
3
 There are four important 
causes of cancer: (a) genetic factors, (b) lifestyle factors, (c) infections, and (d) environmental 
exposures.
4
 Only 5-10% of all cancers can be attributed to genetic causes.
4
 Lifestyle factors play 
a significant role in cancer development and progression. The World Cancer Research Fund 
estimates that 25-33% of new cancer cases in the US in 2013 are related to behavioral and 
lifestyle factors, such as overweight or obesity, physical inactivity, and poor nutrition.
5
 Research 
studies estimate half of the cancer burden can be prevented or significantly reduced by 
modifying lifestyle factors.
6, 7
 
 Lifestyle factors can generate metabolic abnormalities that include overweight and 
obesity, and high blood pressure, cholesterol, and blood glucose. Epidemiologic evidence 
supports the association between each of these individual metabolic risk factors (MRFs) and 
cancer risk.
8-22
 A few studies have also reported that cancer risk increases with the number of 
MRFs.
23-33
  
 Several complex biological mechanisms have been proposed to show metabolic risk 
factors promoting carcinogenesis. In brief, metabolic risk factors, functioning through various 
mechanisms, including increased inflammatory markers, such as tumor necrosis factor-alpha and 
interleuken-6, increased adipokines such as leptin, and decreased adiponectin, increased levels of 
free fatty acids and triglycerides, insulin resistance, increased insulin-like growth factor-1, and 
increased oxidative stress, can cause angiogenesis, cell migration, mitogenesis, and DNA 
damage.
34
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 Despite the epidemiologic studies and limited experimental evidence supporting the 
biological role of MRFs in cancer development and progression, results from studies examining 
the association between individual and combined MRFs and overall cancer are inconsistent. 
Therefore, the goal of this dissertation was to assess the individual and combined effects of 
MRFs on subsequent risk of cancer. It comprises three inter-related studies on cancer risk from 
metabolic risk factors. The background and methods of each of the three papers from the 
dissertation are discussed briefly. 
1.2    Study 1 Background: Metabolic Syndrome is associated with increased breast cancer 
risk: A systematic review with meta-analysis 
 In the first paper of this dissertation, a systematic review with meta-analysis was 
conducted to comprehensively synthesize existing literature on the association between 
metabolic syndrome and breast cancer incidence. The most common cancer in women 
worldwide is breast cancer, which accounted for 1.38 million new cases in 2008, comprising 
approximately a quarter (23%) of  all new cancer cases.
35
 Traditional risk factors for breast 
cancer are well known as age, family history of cancer, and reproductive and menstrual history, 
but lifestyle risk factors such as overweight, lack of physical activity, and consumption of 
alcohol are also crucial.
36
 Several of these risk factors are associated with metabolic syndrome 
(MS).
37
 
 Metabolic syndrome (MS) is a cluster of pathophysiological disorders comprising central 
obesity, insulin resistance, high blood pressure, and dyslipidemia.
37
 MS has been identified as a 
risk factor for several cancers, particularly breast, pancreatic, colorectal, and prostate cancers.
25, 
26, 28, 30-32, 38-45
 Individual components of MS are positively associated with the development of 
certain cancers, most notably breast cancer.
46-52
 Yet, studies show mixed results in these 
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associations.
29, 33, 53
 Although some of the components of MS may not be strongly associated 
with the development of breast cancer, they may all work together to elevate the risk.
34
 This 
possibility suggests that MS may influence breast tumorigenesis by activating different 
molecular pathways through endocrine, metabolic, and immune cell changes.
54
 
 However, results from previous epidemiologic studies are inconsistent with respect to MS 
and breast cancer risk. Given the conflicting results from individual studies of MS and breast 
cancer risk in all adult women, this study used the aggregate data meta-analytic approach to 
examine the association between MS and BC risk in women. Studies were retrieved by searching 
four electronic reference databases [PubMed, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Web of Science, and PROQUEST - June 30, 2012], and cross-referencing 
from retrieved articles. Eligible for inclusion were longitudinal studies that reported associations 
between MS and breast cancer risk among females aged 18 years and older. Relative risks (RR) 
and associated 95% confidence intervals (95% CI) were calculated for each study, and then 
pooled using fixed and random-effects models. Publication bias was assessed both quantitatively 
(trim and fill)
55
 and qualitatively (funnel plots). Heterogeneity was examined using Q and I
2
 
statistics.
56
 
1.3 Study 2 Background: Association between individual and combined metabolic risk 
factors and subsequent risk of cancer  
 Comprehensive reviews provide evidence of association between individual MRFs, such 
as obesity, hypertension, diabetes, hypercholesterolemia, and overall and site-specific cancers. 
Epidemiologic reviews provide evidence of individuals with diabetes at a higher risk for most 
cancers.
9, 10, 12, 16, 18, 49
 Studies also show an association between obesity and several cancers.
11, 13-
5 
 
15, 17, 47, 48, 57-59
 However, results are less consistent for studies examining the association between 
blood pressure, cholesterol, and cancer.
19, 20, 60-66
 
 There is adequate evidence that the risk for heart disease and stroke increases with 
number of MRFs.
67, 68
 A combination of three or more of the MRFs is generally termed as 
metabolic syndrome.
37
 Metabolic syndrome is estimated to be prevalent in over a third of US 
adults.
69
 A recent meta-analysis found that the combination of MRFs (metabolic syndrome) also 
elevated the risk for several cancers.
24
  
 Findings from observational as well as intervention studies have raised the hypothesis of 
an etiologic link between the clustering of MRFs and elevated risk of cancer.
70
 Several complex 
biological mechanisms have been proposed to show that MRFs promote carcinogenesis. The 
prevalence of hyper-insulinemia and insulin resistance is higher in obese individuals. Hyper-
insulinemia reduces the production of  insulin-like growth factor (IGF) binding protein, resulting 
in increased bioavailability of IGF-1.
8
 IGF-1 may promote tumor development by stimulating 
cell proliferation and inhibiting apoptosis. Increased circulating insulin can also reduce the levels 
of sex-hormone-binding-globulin, thereby increasing endogenous sex-steroid levels.
8
 Breast, 
endometrial, and colorectal cancers may be affected by this mechanism.
71
 Another carcinogenic 
mechanism involves cytokines. Increased adiposity raises cytokine production in obese women, 
which in turn can induce estradiol production.
34
 Estradiol is a strong growth factor for breast and 
endometrial cancers. Leptin, another adipocyte-specific hormone, is directly related to adiposity 
and insulin resistance. It has direct stimulatory effects on cancer cells and may serve as an 
important link between obesity and carcinogenesis.
34
 
 However, studies are not consistent in predicting an elevated cancer risk from MRFs. 
With the background of increasing prevalence of metabolic syndrome, and epidemiologic 
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evidence and biologic possibility of the association between MRFs and cancer risk, this study 
examined the association of MRFs (obesity, high blood pressure, high total serum cholesterol, 
and diabetes), individually and in combination, and subsequent risk of overall and site-specific 
cancers of the breast, digestive system, and lung respectively. 
Data were derived from the NHANES I Epidemiologic Follow-up Study, and comprised 
participants ages 25 to 74 years at baseline. Multivariable Cox proportional hazards regression 
models were fitted to assess the association between individual and combined MRFs and cancer 
incidence. Analyses were adjusted for age, race, education, family income, physical activity, 
smoking status, and family history of cancer, and stratified by age and gender. All analyses 
incorporated the complex sample design and sample weights in order to generate national 
estimates. 
1.4 Study 3 Background: Association between metabolic risk factors and age at cancer 
onset 
 Several epidemiologic studies have shown that MRFs elevate the risk of overall and 
several site-specific cancers.
8-22, 23-33
 However, very few studies have examined whether MRFs 
are associated with earlier age at cancer onset. There are a few studies showing overweight, 
obesity, and hypertension being associated with earlier age at cancer onset.
59, 66, 72
  
 Animal studies suggest that mechanisms which prevent metabolic abnormalities, by 
reducing serum IGF-1 or androgen concentrations, may delay the growth and progression of 
breast and prostate cancers.
73
 An animal study found that mammary tumors developed earlier in 
diet-induced obese rats than in lean rats, supporting the role of hormones and adipokines 
(produced by adipose tissue) in cell proliferation and carcinogenesis.
74
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 The aim of this study was to examine whether MRFs, either individually or in 
combination, were associated with age at onset of all-site cancer, and cancer of the breast, 
digestive system, and lung respectively. It is an important research question for several reasons. 
First, studies show that age at onset of certain cancers, such as breast, cervical, and prostate 
cancers, is temporally decreasing.
75
 Second, earlier cancer onset shortens life expectancy, 
signifying major loss of potential years of life.
76-78
 Third, compared with older patients, younger 
cancer patients are likely to have more aggressive cancers, less favorable prognosis, and poorer 
outcomes.
76-78
 Fourth, earlier age at cancer onset in a family may increase cancer risk for the next 
generation.
79, 80
  
 Data were derived from the NHANES I Epidemiologic Follow-up Study, and 
comprised participants ages 25 to 74 years at baseline. The outcome variable was age at cancer 
onset, and the primary metabolic risk factors were obesity, high blood pressure, high total serum 
cholesterol, and diabetes. Analyses were adjusted for age, race, education, family income, 
physical activity, smoking status, and family history of cancer, and stratified by age and gender. 
Multiple linear regression analyses, using the general linear model, were conducted to assess the 
relationship between MRFs and age at cancer onset. All analyses incorporated the complex 
sample design and sample weights to produce national estimates. 
 Each of the three papers is presented in detail in the next three chapters (Chapters 2-4). 
The last chapter (Chapter 5) summarizes the findings from each of the papers and raises key 
discussions points before concluding this research study. 
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CHAPTER 2.  METABOLIC SYNDROME IS ASSOCIATED WITH INCREASED 
BREAST CANCER RISK: A SYSTEMATIC REVIEW WITH META-ANALYSIS 
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2.1 Abstract 
Background 
 While positive and statistically significant associations between individual metabolic risk 
factors and breast cancer risk have been reported, controversy surrounds risk of breast cancer 
from metabolic syndrome (MS). We report the first systematic review and meta-analysis of the 
association between MS and breast cancer risk in all adult females.  
Methods 
 Studies were retrieved by searching four electronic reference databases [PubMed, 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and 
PROQUEST - June 30, 2012], and cross-referencing from retrieved articles. Eligible for 
inclusion were longitudinal studies that reported associations between MS and breast cancer risk 
among females aged 18 years and older. Relative risks (RR) and associated 95% confidence 
intervals (95% CI) were calculated for each study, and then pooled using random-effects models. 
Publication bias was assessed both quantitatively (trim and fill) and qualitatively (funnel plots). 
Heterogeneity was examined using Q and I
2
 statistics.  
Results 
 Representing nine independent cohorts and 97,277 adult females, eight studies met the 
inclusion criteria. A modest, positive association was observed between MS and breast cancer 
risk (RR: 1.47, 95% CI, 1.15-1.87; z = 3.13; p = 0.002; Q = 26.28, p =.001; I
2
 = 69.55%). No 
publication bias was observed.  
Conclusions 
 MS is associated with an increased risk for breast cancer in adult women.  
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2.2 Introduction 
 Breast cancer, the most common cancer in women worldwide, accounted for 1.38 million 
new cases in 2008, comprising approximately a quarter (23%) of  all new cancer cases.
1
 While 
traditional risk factors for breast cancer include age, family history of cancer, and reproductive 
and menstrual history, the National Cancer Institute also recognizes overweight, lack of physical 
activity, and consumption of alcohol as risk factors.
2
 Several of these risk factors are associated 
with metabolic syndrome.
3
 
 Metabolic syndrome (MS) is a cluster of pathophysiological disorders comprising central 
obesity, insulin resistance, high blood pressure, and dyslipidemia. Reaven’s definition of MS in 
1988
4
 was followed by definitions from the World Health Organization,
5
 National Cholesterol 
Education Program's Adult Treatment Panel III (NCEP ATP III),
6
 American Heart 
Association/National Heart, Lung, and Blood Institute,
7
 and the International Diabetes 
Federation.
8
  The NCEP’s ATP III guidelines are the most commonly used criteria in the U.S.6  
These criteria include the presence of three or more of the following
3
: abdominal obesity (waist 
circumference  35 inches in women), triglycerides  150 mg/dL, high density lipoprotein 
cholesterol (HDL-C) < 50 mg/dL, blood pressure (BP)  130/85 mmHg, and fasting glucose  
110 mg/dL. MS is estimated to be prevalent in at least a quarter of the adults in the Americas, in 
Europe, and in India.
9
 
 MS has been identified as a risk factor for several cancers, particularly breast, pancreatic, 
colorectal, and prostate cancers.
10-15
 Individual components of MS, for example, abdominal 
obesity, high blood glucose, high BP, high triglycerides, and low HDL, are positively associated 
with the development of certain cancers, most notably breast cancer.
16-27
 While studies show a 
positive association of breast cancer with diabetes
19, 28-33
 and obesity,
16, 34, 35
 others show a 
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negative association with obesity in premenopausal women.
36-38
 Mixed results also characterize 
hypertension
22, 23,39, 40
 and dyslipidemia
22, 41, 42
 as risk factors for breast cancer.  
 Although individual components of MS may not be strongly associated with the 
development of breast cancer, their combination may elevate the risk.
13, 14, 43-56
  For example, MS 
may activate different molecular pathways through endocrine, metabolic, and immune cell 
changes, which in turn influence breast tumorigenesis.
47
 Such pathways that enhance breast 
cancer cell proliferation and inhibit apoptosis, include:  (1) increased levels of circulating 
estrogen, e.g., estradiol,
52, 54, 57
 (2) higher levels of insulin,
58, 59
 (3) decreased level of circulating 
adiponectin,
60
 and (4) increased plasma leptin concentration.
60
 
 Results from previous epidemiologic studies are inconsistent with respect to MS and 
breast cancer risk. For example, only four
13, 14, 43, 51
 of eight studies
13, 14, 43, 48, 51, 61-63
 reported a 
statistically significant association between MS and risk of breast cancer. Therefore, one might 
conclude that the association between MS and breast cancer risk is unknown. However, such a 
conclusion would be based on the vote-counting approach, an approach that ignores the 
magnitude of the association.
64
  
  A recent systematic review and meta-analysis of MS and postmenopausal breast cancer 
found that MS was moderately associated with the risk of postmenopausal breast cancer.
10
  
However, to the best of our knowledge, no meta-analytic research has addressed the conflicting 
results from individual studies of MS and breast cancer risk in all adult women. Therefore, the 
purpose of this study was to use the aggregate data meta-analytic approach to examine the 
association between MS and breast cancer risk in women.  
2.3 Methods 
2.3.1 Study Eligibility  
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 The a priori inclusion criteria for this study were as follows: (1) observational studies 
using cohort (both prospective and retrospective), case-control, or nested case-control study 
designs; (2) studies examining the association between MS (presence of a cluster of three or 
more metabolic abnormalities) and breast cancer incidence, as defined by the authors; (3) studies 
with adult females ≥ 18 years of age as participants; (4) English-language studies published as 
journal articles, doctoral dissertations, or masters’ theses; (5) published and indexed studies up to 
June 30, 2012; and (6) studies reporting sufficient data (e.g., rate ratios, risk ratios, odds ratios, 
standardized incidence ratios, hazard ratios, or frequencies) for calculating a common effect size. 
 Studies not meeting all inclusion criteria were excluded from this review. Excluded 
studies were those that: (1) were not published as full reports, such as conference abstracts and 
letters to editors; (2) only examined individual components of MS; (3) measured the MS 
variables at the time of cancer diagnosis; (4) used cancer mortality, rather than incidence, as the 
outcome; and (5) studies published in a language other than English.  
2.3.2 Data Sources  
 A comprehensive and systematic search was conducted using four electronic databases: 
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, 
and PROQUEST (from their commencement to June 30, 2012). Since the term MS dates back to 
the late 1950s, with variations in use as early as the 1920s, the start dates of each of the databases 
were used as the commencement date for study search; Web of Science (1900), CINAHL (1952), 
PubMed (1966), and Proquest (1861).  In addition, cross-referencing from retrieved studies was 
also performed. Major keywords used in the search for potentially eligible studies included 
“metabolic syndrome” (“insulin resistance syndrome,” “syndrome x,”) and “breast cancer” 
(“neoplasm and breast”). Using the most recent publication, trials published as duplicate reports 
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(parallel publications) were only included once. All electronic searches were conducted using the 
graphical user interface for each database. The last search was conducted on June 30, 2012.  
2.3.3 Study Selection  
 At the first screening, one author screened all abstracts and selected articles for full-text 
examination. At the second level of the study selection process, two of the authors examined the 
full-text articles and then selected the included studies following mutual discussion and 
consensus. 
2.3.4 Data Extraction  
 Two of the authors reviewed every study selected and independently extracted data from 
studies onto electronic coding forms. These forms could hold up to 52 items per study. Attempts 
were made to contact authors of three of the original studies for missing information,
13, 61, 63
 but 
only one provided the requested information.
13
 After initial coding, the two coders reviewed each 
item for agreement. Discrepancies were resolved by consensus. Using Cohen’s kappa (k) 
statistic,
65
 the overall inter-rater agreement rate prior to correcting discrepant items, was 0.96 for 
all included studies.    
2.3.5 Risk of Bias Assessment   
 Risk of bias was assessed using a modified version of the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) checklist.
66
  The items assessed included: (1) 
study design, (2) adjustments for confounders, (3) selection of participants and their eligibility 
criteria, (4) measurement of predictor variables, (5) breast cancer diagnosis, (6) study size, (7) 
handling of missing data, and (8) reasons for non-participation of individuals at each stage of the 
study. A description of the criteria for risk of bias assessment is shown in Table 1. Two of the 
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authors conducted all assessments, independent of each other. Disagreements were resolved 
through discussion. No study was excluded based on the results of the risk of bias assessment. 
2.3.6 Statistical Analysis 
 Calculation of study-level effect sizes. Risk estimates were used to examine the 
association between MS and risk of breast cancer. These were derived from reported relative 
risks, odds ratios, hazard ratios, incident rate ratios, or standardized incidence ratios, together 
with their respective 95% CIs, from the original studies. Where necessary and possible, all 
metrics were converted to risk ratios (RRs).  Adjusted risk estimates from multivariable models 
in the original studies were pooled for analysis.  However, for two case-control studies that were 
included,
14, 51
 adjusted odds ratios were used because data necessary to convert to RR were not 
available.  
 Effect size pooling. All RR results were pooled using a random-effects model, an 
approach that incorporates between-study heterogeneity into the model.
67
 A z-score two-tailed 
alpha value ≤0.05 was considered as statistically significant. In addition, 95% confidence 
intervals (CIs) were calculated for each result from each study as well as for pooled estimates. 
Heterogeneity was calculated using the  Q
68
 and I
2 
statistics.
69 
An alpha level ≤ 0.10 for the Q 
statistic was considered as evidence of statistically significant heterogeneity. While somewhat 
arbitrary, I
2
 values of 25%, 50%, and 75% were considered to represent low, moderate and high 
amounts of heterogeneity.
69
 Publication bias was assessed using the Trim and Fill approach of 
Duval and Tweedie.
70
 In addition, Rosenthal’s Fail-Safe N test was used to compute the number 
of missing null studies that would be needed to nullify the overall pooled RR as being 
statistically significant.
71
 Statistically significant standardized residuals (p < 0.05) were 
considered as outliers.    
21 
 
 Sensitivity analyses. In order to examine the effects of each result from each study on the 
overall pooled results, influence analysis was conducted with each result from each study deleted 
from the model once.  Cumulative meta-analysis, ranked by year, was also conducted in order to 
examine the accumulation of results over time. A separate pooled analysis limited to 
postmenopausal women was conducted because studies show that MS in postmenopausal women 
increases the risk of breast cancer.
13, 14, 43, 48, 51, 61
  In addition, pooled analyses were conducted 
with the following caveats post hoc: (1) deletion of results from two case-control studies because 
odds ratios were used instead of RR,
14, 51
 (2) deletion of results from studies that were not 
prospective cohort designs,
13, 14, 51
 and (3) limiting the results to studies that controlled for four 
or more of the important confounders (as listed in Table 1).
14, 43, 48, 51
 All analyses were 
performed using Comprehensive Meta-Analysis, Version 2.2.
72
 
2.4 Results 
2.4.1 Study Characteristics 
 Figure 1 presents a flow diagram of the selection of studies for the meta-analysis. Of the 
291 studies screened, 47 (16.2%) were selected for full-text review: 25 from PubMed,
14, 43-55, 63, 
73-82
 17 from the Web of Science,
13, 39, 62, 83-96
 one from CINAHL,
97
 and four from ProQuest.
61, 98-
100
 Of the 47 that underwent a full-text review, eight (17.0%) met the eligibility criteria.
13, 14, 43, 
48, 51, 61-63
 One article
14
 presented results for two independent cohorts; therefore, each cohort was 
treated independently. 
 A general description of the included studies is shown in Table 2. Studies were published 
between 2008 and 2012 and from five different countries. The study designs included four 
prospective cohorts,
48, 61-63
 one retrospective cohort,
13
 one prospective nested case-control,
43
 and 
two case-control.
14, 51
 The baseline year for cohort inception ranged from 1983 to 2004, with 
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average follow-up ranging between 2.7 and 13.5 years. Sample sizes ranged from 792 to 49,172 
(total 97,277) adult females, excluding one study that did not report this data.
63
 The ages of the 
participants ranged from 21 to 86 years. Six studies conducted analyses on postmenopausal 
women.
13, 14, 43, 48, 51, 61
 The results of each cohort or case-control study were initially reported as 
a hazard ratio,
13, 48, 62
 incidence rate ratio,
43, 61
 standardized incidence ratio,
63
 or odds ratio.
14, 51
  
Methods for exposure assessment, cancer identification and the controlling of confounders varied 
across the eight included studies (Table 3). Seven of the eight studies identified the outcome 
(breast cancer) through histological reports, medical reports, or from a cancer registry,
13, 14, 43, 48, 
51, 61, 63
 while one used self-report.
62
 Only three studies examined invasive breast cancer cases.
43, 
48, 63
 One study also reported on the in situ breast cancer cases but there were only seven such 
cases in that study.
43
 Another study analyzed all breast cancer cases (in situ and invasive) as well 
as invasive cancers separately, and the results remained the same in both analyses.
48
  
2.4.2 Risk of Bias Assessment  
 Risk of bias results are shown in Table 4. All the studies were considered to be at low 
risk for selection of participants and meeting eligibility criteria as well as providing adequately 
powered sample sizes. Out of eight studies, a majority were also considered low risk with respect 
to study design (six studies) and measurement of the outcome variable (seven studies). In terms 
of handling potential confounders, half the studies were low risk, three were high risk, and one 
was unclear.  Missing confounding variables included education, smoking status, alcohol use, 
family history of cancer, contraceptive use, or hormonal history. Similarly, half the studies had 
objective measurements of predictor variables, while the remainder relied on self-report, and 
were consequently considered high risk. Four studies deleted the participants with missing 
variables in their analyses (high risk), while two did not report how they handled missing data. 
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Lastly, six studies were considered high risk because they did not report the reasons for non-
participation of subjects at each stage of follow-up. 
2.4.3 Statistical Analysis 
 Overall Results. Overall, a statistically significant increase of 47% in the risk for incident 
breast cancer was observed for adult females with MS (RR: 1.47, 95% CI, 1.15-1.87; z = 3.13; p 
< 0.002; Q = 26.28, p <0.001; I
2
 = 69.55%) (Figure 2). With the exception of one study,
62
 all 
other studies had RR in the direction of increased risk.
13, 14, 43, 48, 51, 61, 63
 Funnel plot results for 
potential publication bias are shown in Figure 3. Using the Trim and Fill approach that resulted 
in two imputations, the risk decreased by 16% but remained significant (RR: 1.31, 95% CI, 1.01-
1.70). The fail-safe N was 69, implying that 69 'null' studies would be needed to nullify the 
statistically significant association between MS and breast cancer risk in adult females.  No 
statistically significant outliers were identified (p = 0.06-0.82).   
 Sensitivity analysis. With each study deleted from the model once, results remained 
positive and statistically significant (Figure 4). As can be seen, the pooled RR fell within a range 
of 20% (RR = 1.36-1.56) and none of the CIs for the point estimates was less than 1.0. 
Cumulative meta-analysis, ranked by year, revealed that results have been statistically significant 
since 2011 (Figure 5). Deleting the two case-control studies from the model, the RR for incident 
breast cancer for women with MS decreased by 18% but was still statistically significant with 
moderate heterogeneity (RR: 1.29, 95% CI, 1.003-1.67; z = 1.98; p = 0.05; Q = 14.13, p = .01; I
2
 
= 64.61%). When limited to studies with only prospective designs, the RR decreased by 30% but 
remained statistically significant with very low heterogeneity (RR: 1.17, 95% CI, 1.01-1.36; z = 
2.04; p =0.04; Q = 4.30, p = 0.37; I
2
 = 7.04%). When limited to postmenopausal women, breast 
cancer risk increased by 34% and was still statistically significant with high heterogeneity (RR: 
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1.81, 95% CI, 1.28-2.56; z = 3.37; p =0.001; Q = 23.36, p =0.001; I
2
 = 74.32%). Lastly, when 
limiting the results to studies that controlled for four or more of the important confounders (as 
listed in Table 1),
14, 43, 48, 51
 breast cancer risk increased by 17% and was statistically significant 
with moderate heterogeneity (RR: 1.64, 95% CI, 1.23-2.20; z = 3.34; p =0.001; Q = 8.55, p 
=0.07; I
2
 = 53.21%).   
2.5 Discussion 
 The purpose of this aggregate data meta-analysis was to examine the association between 
MS and the risk for breast cancer in adult females. Overall results suggest that a modest positive 
association exists between MS and risk of breast cancer. This finding is strengthened by the 
robustness of results from other analyses. These include: (1) examination for publication bias, (2) 
influence analysis with each study deleted from the model once, (3) deletion of the two case-
control studies with odds ratios from the overall model, (4) limiting the analysis to prospective 
designs, (5) including only postmenopausal women in the analysis, and (6) limiting the results to 
studies that controlled for four or more of the important confounders. The results from 
cumulative meta-analysis, ranked by year, indicate an increasingly statistically significant 
association since 2011. 
 Assessment for risk of bias indicated that a majority of studies were at low risk regarding 
study design, cancer assessment, and sample size. However, a majority were at high risk or 
unclear risk in terms of handling of missing data and non-participation of subjects at each stage 
of follow-up. It is suggested that future studies provide complete information on the handling of 
missing data and on the non-participation of subjects at each stage of follow-up. 
 When limited to postmenopausal women, a stronger association between MS and breast 
cancer was observed. This association was stronger in case-control and retrospective cohort 
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study designs compared with prospective cohort study designs. These findings concur with the 
recent meta-analysis on MS and breast cancer risk in postmenopausal women.
10
 Several studies 
have shown that MS in postmenopausal women increases the risk of breast cancer,
43, 46, 101
 
suggesting that the etiology of breast cancer may differ among pre and postmenopausal women.  
 There are several potential mechanisms linking MS with the increased risk of breast 
cancer. First, obese postmenopausal women produce higher levels of estrogens, which in turn 
increase the biologically available fraction of circulating estradiol by reducing plasma 
concentration of sex hormone binding globulin (SHBG).
102
 Low plasma SHBG levels are 
associated with insulin resistance
103, 104
 and other components of MS.
105, 106
 Second, adipose 
tissue produces two adipokines (cytokine-like factors), leptin and adiponectin, that affect breast 
cancer biology.
107
 Higher plasma leptin levels are associated with obesity,
54, 57, 108
 insulin 
resistance,
109, 110
 and MS.
111, 112
 Leptin stimulates human breast cancer cell lines, whereas 
adiponectin acts protectively, inhibiting the growth of these cell lines.
57, 107, 113
 Obesity is 
associated with reduced adiponectin levels.
114
 Third, insulin has been shown to have a mitogenic 
effect upon breast cancer cells in vitro through several mechanisms.
57
 It can act synergistically 
with estradiol and stimulate proliferation of the cell line.
115
 Insulin can also lower SHBG 
production,
116
 thereby increasing biologically available estradiol. Moreover, low serum HDL-C 
concentrations indicate higher circulating bioactive estrogen levels, which in turn may stimulate 
target breast tissue.
76
 
 The increasing prevalence of MS, and its association with breast cancer, among other co-
morbidities, point toward the critical need to develop public health strategies to manage MS. 
Given the increasingly large global burden of metabolic risk factors, even a small association 
with breast cancer can have a substantial public health impact. Risk assessment tools can be 
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developed that incorporate MS as a risk factor for breast cancer. Healthcare providers will then 
be better equipped to identify high-risk women for primary and secondary prevention. 
 This study has several strengths. First, to the best of our knowledge, this is the first 
systematic review and meta-analysis to examine the association between MS and risk of breast 
cancer in all adult women. The analysis incorporates all women, and a sub-analysis of post-
menopausal women. The overlapping meta-analysis on metabolic syndrome and breast cancer 
was confined to post-menopausal women only.
10
 Second, a number of other analyses were 
performed that strengthened the robustness of findings. Third, the results of this study provide 
direction for future research on this topic. 
 This study also has several potential limitations. These include (1) the  different methods 
used to assess exposure, identify cancer, control for confounders, and define MS, (2) limiting 
studies to those published in English, which may have led to inflated results,
117
 (3) the relatively 
small number of studies that met the inclusion criteria, (4) the inability of some studies to 
provide raw data for calculating the RR, (5) the different study designs employed, and (6) the 
varied populations studied.  
 In order to inform and undergird a biological rationale for the observed positive 
association between MS and breast cancer risk in adult females, future studies should consist of 
analyses based on a standard definition of MS and employ objective and standard biomarkers for 
assessing each MS component. In addition, adjustments for all important potential confounders 
need to be made. It would be helpful if future studies examined the relationship between MS and 
breast cancer risk separately in perimenopausal and premenopausal women since breast cancer in 
women may be estrogen-independent.  Along those lines, not all studies adjusted for hormone 
replacement therapy, a potential confounder.  Future studies should report this information. 
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Furthermore, future research needs to examine in situ and invasive cancers separately in relation 
to metabolic syndrome. Finally, a focus on obese women with respect to MS and breast cancer 
seems appropriate.   
 In conclusion, the overall results of this meta-analysis suggest that there is a modest 
positive association between MS and risk of breast cancer in adult females.  
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Tables and Figures 
The working tables and figures can be found in Appendix A. 
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CHAPTER 3.  ASSOCIATION BETWEEN INDIVIDUAL AND COMBINED 
METABOLIC RISK FACTORS AND CANCER RISK  
39 
 
3.1 Abstract 
Introduction 
 Cancer is the second most common cause of death in the United States. A third of the 
cancer burden is estimated to be associated with metabolic risk factors (MRFs), such as obesity, 
high blood glucose, hypertension, and dyslipidemia. However, studies have shown inconsistent 
results for the association between these MRFs and cancer risk. The aim of this study was to 
examine whether MRFs, either individually or in combination, were associated with the 
subsequent risk of overall and selected site-specific cancers of the breast, digestive system, and 
lung.  
Methods 
Data were derived from the NHANES I Epidemiologic Follow-up Study, and comprised 
participants ages 25 to 74 years at baseline. Multivariable Cox proportional hazards regression 
models were fitted to assess the association between individual and combined MRFs (obesity, 
high blood pressure, high total serum cholesterol, and diabetes) and cancer incidence. Analyses 
were adjusted for age, race, education, family income, physical activity, smoking status, and 
family history of cancer, and stratified by age and gender. All analyses incorporated the complex 
sample design and sample weights in order to generate national estimates. 
Results 
 Diabetes, high BP, and the presence of a combination of three or four MRFs were 
associated with higher breast cancer risk among postmenopausal women. Obesity in males less 
than 50 years of age elevated the risk of digestive cancer.  
Conclusion 
40 
 
 In this large, prospective cohort study, MRFs, either individually or aggregated, were not 
consistently associated with cancer risk in either men or women. The association of individual 
and combined MRFs was stronger with postmenopausal breast cancer risk. 
41 
 
3.2  Introduction 
 The “plague of our generation,”1 cancer is the second most common cause of death in the 
United States. The American Cancer Society estimates 1.7 million new cancer cases in 2013.
2
 
Cancer incidence rates per 100,000 persons (age-adjusted to the 2000 US standard population) 
for 1995-2009 were 550.7 and 419.3 for males and females, respectively.
2
  
 Lifestyle factors, such as diet, obesity, physical activity, and smoking, play a significant 
role in carcinogenesis. Approximately half of the cancer burden can be prevented or significantly 
reduced by modifying lifestyle factors.
3, 4
 Lifestyle factors can generate metabolic abnormalities 
that include overweight and obesity, and high blood pressure, cholesterol, and blood glucose.  
 Each of the aforementioned abnormalities has been separately implicated as a metabolic 
risk factor (MRF) for cancer.
5-25 
Comprehensive reviews provide adequate evidence of an 
association between obesity and several cancers in both men and women.
14, 15, 17, 18, 26-28
 
Similarly, epidemiologic studies and reviews show that individuals with diabetes are at a higher 
risk for most cancers, although the association is unclear for prostate and lung cancers.
7, 12, 13, 16, 
19, 29-32
 Elevated blood pressure is also associated with several cancers, although the results are 
inconsistent across studies.
7, 10, 25
 Results for the association between total serum cholesterol and 
cancer are similarly inconclusive.
33
  
 Research indicates that the risk for heart disease and stroke increases with number of 
MRFs.
34, 35
 A few studies have also indicated a similar pattern of increased risk for certain types 
of cancer from combined MRFs.
6-10, 20-23, 36-38 
A combination of three or more of the MRFs is 
generally termed as metabolic syndrome.
39
 It is estimated to be prevalent in a third of US 
adults.
40
 A meta-analysis on risk of various cancers found that metabolic syndrome elevated the 
risk for liver, colon, colorectal, pancreatic, thyroid, rectal, bladder, and prostate cancers in men, 
42 
 
and endometrial, pancreatic, breast, rectal, liver, colorectal, colon, and ovarian cancers in 
women.
6
  
 Each individual MRF can promote cancer through an independent biological mechanism. 
In turn, these mechanisms can complement each other, and act additively to promote cancer 
development. MRFs, functioning through various mechanisms, including increased 
inflammatory markers, such as tumor necrosis factor-alpha and interleuken-6, increased 
adipokines such as leptin,  and decreased adiponectin, increased levels of free fatty acids and 
triglycerides, insulin resistance, increased insulin-like growth factor-1, and increased oxidative 
stress, can cause angiogenesis, cell migration, mitogenesis, and DNA damage.
41-43
 
 The prevalence of MRFs is high, and continues to rise.
44
 At the same time, there is 
epidemiologic evidence of the association of MRFs with several cancers. Moreover, there are 
few animal studies supporting the biological role of MRFs in cancer development and 
progression. However, results from studies examining the association between individual and 
combined MRFs and overall cancer are inconsistent. Therefore, this study examined the 
association of MRFs (obesity, high blood pressure, high total serum cholesterol, and diabetes), 
individually and in combination, and subsequent risk of overall and site-specific cancers of the 
breast, digestive system, and lung. 
3.3 Methods 
 3.3.1 Data Source and Study Population: Data were derived from the NHANES I 
Epidemiologic Follow-up Study (NHEFS). The NHEFS is a national, multi-stage, stratified 
probability sample of the non-institutionalized, civilian population in the U.S.
45
 It includes 
participants from the NHANES I (National Health and Nutrition Examination Survey I) cohort 
aged 25-74 years who completed a medical examination at baseline (1971-75). Participants were 
43 
 
followed-up in 1982-84, 1986, 1987, and 1992. Only 5% of the original NHEFS sample was lost 
through attrition.
46
  
 Baseline data were acquired by merging five NHANES I datasets on anthropometry, 
biochemistry, medical history, medical needs, and medical examination. Since the NHEFS 
follow-up was conducted for participants aged ≥ 25 years and ≤ 74 years at the time of NHANES 
I interview, only this group was retained for the analysis. Cancer status was determined by 
merging data from each of the 1982-84, 1986, 1987, and 1992 surveys, in addition to the NHEFS 
vital statistics data. 
 The status variable, incident cancer cases, was defined using the International 
Classification of Diseases-9th revision (ICD-9), codes 140-208, excluding ICD-173 (skin 
cancer), and were followed up through interview and death certificate data. All cancer cases 
since the baseline period were obtained from the first, second and third diagnoses of cancer, 
along with their location (cancer-site). Skin cancer cases were not included among total cancer 
cases, since their etiology is different and does not involve MRFs. For subjects with multiple 
cancers, only the first occurring non-skin cancer was included. Year of death was used for cancer 
incidence if a death certificate was the only source of cancer information.  
 Study participants were considered to be at risk for cancer from their date of first 
examination until date of diagnosis of cancer, or death, or termination of follow-up, whichever 
occurred first. Event times were censored for participants who had not developed cancer by the 
end of follow-up or died from non-cancer causes. 
 A total of 14,407 persons from the NHANES dataset were followed up until 1993. Of 
these, 684 had a cancer diagnosis at baseline (determined from the question: Has a doctor ever 
told you that you have malignant tumor or growth?) or who died in the same year of examination 
44 
 
and were excluded from analysis. In order to reduce the possibility of reverse causation, another 
146 who developed cancer in the first two years of the study were excluded from analysis. 
Participants with missing values on cancer status (n = 2,310), and on the covariates in the 
multivariable model (n=573) were also excluded from the analysis. The final sample was 10,694 
persons who were cancer-free at the beginning of their study period. 
Information on the following predictor variables was obtained from the baseline 
examination: obesity, assessed as body mass index in kg/m
2
; resting systolic (SBP) and diastolic 
(DBP) blood pressure, measured as continuous variables in mmHg; total serum cholesterol, 
measured as continuous variable in mg/dL; and self-reported diabetes, coded as a dichotomous 
variable. Resting SBP and DBP were measured by a physician using a sphygmomanometer at the 
beginning of the physical examination while the subject was in a sitting position, as consistent 
with American Heart Association guidelines.
47
 All of these readings were retrieved from 
NHANES I medical exam questionnaire. Total serum cholesterol was assessed using a semi-
automated instrument in the Centers for Disease Control and Prevention's lipid standardization 
laboratory. Information on diabetes was gathered from NHANES I medical history questionnaire 
(Has a doctor ever told you had diabetes?) or from NHANES I healthcare needs questionnaire 
(Did a doctor tell you had diabetes? or, do you take any diabetes medicine or insulin?).  
 Analyses were adjusted for the following potentially confounding variables: age, race, 
education, family income, physical activity, smoking status, and family history of cancer. The 
baseline medical history questionnaire provided information on age, race, education, family 
income, and physical activity. At baseline, information on smoking status was very limited, and 
information on family history of cancer was not collected. Therefore, smoking information was 
45 
 
combined from the baseline and 1982 surveys, and information on family history of cancer was 
derived from the latter survey.
48-51
 
3.3.2 Statistical analysis 
 Multivariable Cox proportional hazards regression models, with time since measurement 
as the time variable, and incident cancer cases as study events, were fitted to obtain hazard ratios 
of cancer incidence from MRFs. The model accounted for differential entry and exit times 
among the NHEFS participants. A time-interaction test was conducted with individual and 
combined MRFs in the full model with overall cancer to check whether the assumption of 
proportionality of hazard ratios over time was met. 
 Metabolic risk factors were classified as: (1) obesity: BMI≥ 30 kg/m2; (2) high blood 
pressure: systolic BP ≥ 140 mm/Hg and/or diastolic BP ≥ 90 mm/Hg); (3) high cholesterol: total 
serum cholesterol ≥ 240 mg/dL; and (4) diabetes: presence or absence of diabetes. The effect of 
individual MRF was assessed relative to the absence of that risk factor.  
 Analyses were adjusted for the following potential confounding variables: age, sex, race 
(white versus other), education (high school or less vs. above high school), family income 
(<$5,000, $5,000 to <$15,000, and >=$15,000, based on the poverty line for 1971-75, which was 
set at or below $5,000 as the annual income for a household of four members), physical activity 
(moderately active or very active vs. quite inactive), smoking (smoked 100 cigarettes in one's 
lifetime), and family history of cancer (dichotomous). In the NHANES I dataset, race was 
classified as white, black, or other at baseline. However, for this study, the latter two categories 
were combined and classified as nonwhite due to small numbers.
48
  
 Age was included in all models as an independent, continuous variable. In addition, 
analyses were further stratified by age categorized as <50 and ≥ 50 years as at baseline. The 
46 
 
rationale for this dichotomization was based on previous research that showed that adults 50 
years and older bear the greatest cancer burden, with the largest proportion of cancer being 
diagnosed in this age group.
52
 Another consideration was the biological changes, especially in 
women, which occur around age 50. In addition to age, analyses were also stratified by gender. 
 Besides examining the association between individual MRFs and cancer risk, a second 
analysis assessed the combined effect of MRFs on the risk of overall cancer. An additive 
summary of MRF scores was created by combining the individual MRFs. A score of three was 
assigned to participants with three or more MRFs. The summary score ranged from 0 (no MRF, 
the referent category) to 3 (three or four risk factors). Analyses were adjusted for the following 
potential confounders; age, race, education, family income, physical activity, smoking, and 
family history of cancer, and stratified by gender and dichotomized age. 
 Site-specific cancer (breast, digestive, and lung) were examined separately in evaluating 
an association between individual MRFs as well as the combined MRF score, and cancer risk. 
Cancers of the digestive system included those of the alimentary canal below the neck (i.e., 
esophagus, stomach, small and large intestines) and key digestive organs (i.e., pancreas, liver, 
and gallbladder).  
 In order to test the robustness of results, three different sensitivity analyses were 
conducted. Analysis one included all years of cancer incidence data after the baseline exam; 
analysis two excluded persons with missing data for diabetes; and analysis three was conducted 
with continuous variables for BMI, BP, and cholesterol. 
 All data were analyzed using the complex samples module in IBM SPSS Statistics for 
Windows, version 21.0 (Armonk, NY: IBM Corp). These analyses incorporated the complex 
sample design and sample weights in order to produce national estimates.
53
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3.4 Results 
 Time-interaction test with individual and combined MRFs in the full model with overall 
cancer showed that the assumption of proportional hazards was not violated in the Cox 
proportional hazards regression analyses. Table 1 presents the baseline characteristics of the 
study population, incorporating the sampling weights and design specifications. Mean age at 
baseline was 48.8 years. Among 10,694 persons followed-up between 1971 and 1993, 59% were 
female, and most were white. Over a quarter of the sample had an annual family income below 
poverty level, and about three quarters had an education less than college. Most participants 
reported being moderately or very active in their non-recreational activity, and over half had 
smoked at least 100 cigarettes during their lifetime. A third of the participants reported having a 
family history of cancer. About 16.6% were obese, a little less than half had high BP, a third had 
high cholesterol, and half of the sample had one or more MRFs.  
 Tables 2 and 3 present the association between individual MRFs and cancer risk among 
males and females, respectively, after adjusting for potential confounding factors, and stratifying 
by age. Individual MRFs were not significantly associated with cancer risk in males in the 
multivariable Cox proportional hazards regression analyses, after controlling for age, race, 
education, family income, physical activity, smoking, and family history (Table 2). A decreased 
risk of overall cancer was observed among obese women 50 years of age and older (Table 3). 
High total cholesterol elevated the risk of overall cancer in older women. No association was 
observed in either gender between combined MRFs and overall cancer risk (Tables 4 and 5). 
Tables 6 and 7 present the association of individual and combined MRFs respectively 
with breast cancer risk in all women and postmenopausal women. High BP, diabetes, and 
presence of a combination of three or four MRFs were associated with elevated breast cancer 
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risk in postmenopausal women. Obesity in males elevated the risk of digestive cancer (Table 8). 
Presence of a single MRF in women was associated with reduced risk of digestive cancer (Table 
9). There was no association of MRFs with lung cancer in either gender (Tables 10 and 11). 
 Results were consistent with the main analysis in all sensitivity analyses. However, two 
associations in the main analysis (high cholesterol with increased overall cancer risk, and obesity 
with reduced overall cancer risk in older women) were not observed in other sensitivity analyses. 
3.5 Discussion 
 In this large, prospective cohort study, MRFs, either individually or in the aggregate, 
were not consistently associated with cancer risk in either gender. Overall, diabetes, high BP, and 
the presence of a combination of three or four MRFs were associated with higher breast cancer 
risk among postmenopausal women. Obesity in males less than 50 elevated the risk of digestive 
cancer. 
 Study results show an association between diabetes and increased risk of breast cancer in 
postmenopausal women. A meta-analysis on diabetes and breast cancer showed that among 
postmenopausal women, diabetes was associated with a 16% increased risk of breast cancer.
16
 
Similarly, another recent meta-analysis showed a significant positive association of high blood  
pressure and high glucose/diabetes with postmenopausal breast cancer.
8
 Diabetes is frequently 
associated with insulin resistance, increased circulating concentrations of insulin, and insulin-like 
growth factors. Studies have shown insulin has mitogenic effects on breast tissue.
54
 In addition, 
insulin inhibits the production of sex hormone-binding globulin, resulting in an increase in 
bioavailable estradiol. Increased estradiol levels have been associated with the risk of developing 
breast cancer.
16, 55
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 The finding that postmenopausal women with high BP were at an increased risk of breast 
cancer  is also supported by the recent meta-analysis on breast cancer risk in postmenopausal 
women.
8
 Cancer and hypertension are both characterized by the proliferation of smooth muscle 
cells.
56
 Another hypothesis indicates abnormalities
 
of carcinogen binding to DNA in 
lymphocytes of hypertensive
 
women.
57
                                                                                           
 The results showed a decreased risk of overall cancer from obesity, and an elevated risk 
from high total cholesterol in women 50 years of age or older. However, in the sensitivity 
analyses, these two results were not supported. Epidemiologic evidence suggests obesity is 
associated with increased risk of site-specific cancers in women, such as cancers of 
postmenopausal breast, esophagus, pancreas, endometrium, ovary, thyroid, and kidney.
5, 15, 58-60
 
The question regarding the association between total cholesterol and cancer risk remains 
unresolved in literature.
61
 
 When combined MRFs were examined, postmenopausal women with three or four MRFs 
were observed to be at a higher risk of breast cancer. A recent meta-analysis showed that the 
combined effect of MRFs on increased risk for postmenopausal breast cancer was greater than 
that of individual MRFs.
8
 A combination of MRFs may activate different molecular pathways 
through metabolic, endocrine, and immune cell changes, which can result in breast 
tumorigenesis.
62
 
 Among men, the only significant association observed was between obesity and elevated 
risk of digestive cancer. Other studies have also observed a similar association between 
overweight/ obesity and digestive cancers, such as pancreatic
63, 64
 and colorectal cancers
30
 in 
men. There is also an elevated risk of adenocarcinoma of the esophagus and gastric cardia with 
increasing BMI.
65
 In obese persons, there is an increase in free fatty acids, cytokines, and 
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hormones, resulting in increased insulin levels and insulin-like growth factor. High levels of 
insulin or insulin-like growth factors can promote digestive cancers by promoting cellular 
proliferation and inhibiting apoptosis.
63
 
 Several complex biological mechanisms have been proposed to show that MRFs promote 
carcinogenesis. The prevalence of hyper-insulinemia and insulin resistance is higher in obese 
individuals. Hyper-insulinemia reduces the production of  insulin-like growth factor (IGF) 
protein, resulting in increased bioavailability of IGF-1.
30
  IGF-1 may promote tumor 
development by stimulating cell proliferation and inhibiting apoptosis. Increased circulating 
insulin can reduce the levels of sex-hormone-binding-globulin, thereby increasing endogenous 
sex-steroid levels.
30
 Breast, endometrial, and colorectal cancers may be affected by this 
mechanism.
66
 Another carcinogenic mechanism involves cytokines. Increased adiposity raises 
cytokine production in obese women, which in turn can induce estradiol production.
41
 Estradiol 
is a strong growth factor for breast and endometrial cancers. Leptin, another adipocyte-specific 
hormone, is directly related to adiposity and insulin resistance. It has direct stimulatory effects on 
cancer cells and may serve as an important link between obesity and carcinogenesis.
41
 
 Study results show the association of MRFs with overall and site-specific cancers varies 
by gender. These differences in the association between MRFs and cancer can arise for several 
reasons. Animal studies suggest that production of a protein, interleukin-6, which promotes 
inflammation, is linked to a higher incidence of liver cancer in men than in women.
67
  
The current study has several potential limitations. For example, blood glucose levels 
were not measured directly, but rather, a self-reported diagnosis of diabetes indexed high levels. 
In addition, while total serum cholesterol levels were measured directly, there were no separate 
measures for triglycerides, or low and high-density lipoprotein cholesterol levels (LDL and 
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HDL). This may be important, since previous research has shown that high HDL may be 
inversely associated with site-specific and overall cancer.
68
 However, a systematic review with 
meta-analysis showed no association between triglyceride or HDL levels and such site-specific 
cancers as colorectal cancer.
9
 Although models were adjusted for race, stratified analysis could 
not be performed due to small sample size for races other than white. For this reason, nonwhite 
were combined into one category, although studies have observed racial differences in MRFs.
69
 
Analyses on lung and digestive cancer could not be stratified by age because of small number of 
cancer cases. 
  This study has several strengths. For example, data were derived using a strong 
longitudinal cohort study design with high follow-up rates. Specifically, 96% of the study 
population was successfully traced at some point through the 1992 follow-up.
46
 It is a large, 
nationally representative sample of the US population. All analyses utilized complex sample 
survey design for results representative of the population. In addition, self-report bias tended to 
be minimized because MRFs, such as total serum cholesterol, as well as blood pressure and 
anthropometry (BMI), were based on body measurements and laboratory data. 
 In conclusion, MRFs, either individually or in the aggregate, were not consistently 
associated with cancer risk in either gender in this large, prospective cohort study. The 
association of individual and combined MRFs was stronger with postmenopausal breast cancer 
risk. 
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The working tables can be found in Appendix B. 
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CHAPTER 4.  ASSOCIATION BETWEEN METABOLIC RISK FACTORS AND AGE 
AT CANCER ONSET 
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4.1 Abstract 
Introduction 
 Cancer is the second most common cause of death in the United States. There is evidence 
that components of metabolic syndrome, a cluster of pathophysiological disorders comprising 
obesity, insulin resistance, hypertension, and dyslipidemia, elevate cancer risk. However, there is 
scant literature on the association between the components of metabolic syndrome and age at 
cancer onset. The aim of this study is to examine whether metabolic risk factors (MRFs), either 
individually or in combination, are associated with age at onset of all-site cancer, and cancer of 
the breast, digestive system, and lung, respectively.  
Methods 
Data were derived from the NHANES I Epidemiologic Follow-up Study, and comprised 
participants ages 25 to 74 years at baseline. The outcome variable was age at cancer onset, and 
the primary metabolic risk factors were obesity, high blood pressure, high total serum 
cholesterol, and diabetes. Analyses were adjusted for age, race, education, family income, 
physical activity, smoking status, and family history of cancer, and stratified by age and gender. 
Multiple linear regression analyses, using the general linear model, were conducted to assess the 
relationship between MRFs and age at cancer onset. All analyses incorporated the complex 
sample design and sample weights to produce national estimates. 
Results 
 Study results showed an increased risk of diabetes associated with earlier age at (a) 
cancer onset in younger and older males, (b) cancer onset in older females, (c) postmenopausal 
breast cancer onset, and (d) lung cancer onset in both genders. Presence of a combination of 
three or four MRFs was associated with earlier age at onset of: (a) overall cancer in women 50 
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years and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, and (d) lung 
cancer in males. 
Conclusion 
 Overall, diabetes and a combination of three or four MRFs were found to be associated 
with earlier age at onset of overall and site-specific cancers. The association with combined 
MRFs was stronger in women. Future research needs to determine the underlying mechanisms 
that may predispose people with metabolic abnormalities to cancer.  
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4.2 Introduction 
 Accounting for one in four deaths, cancer is the second most common cause of death in 
the United States (U.S.) after heart disease.
1
 The National Cancer Institute estimates 1.7 million 
new cancer cases in 2013.
2
 Annualized cancer incidence rates for 2006-2010 were 535.9 and 
411.2 per 100,000 males and females, respectively.
2
 The World Cancer Research Fund estimates 
that 25-33% of new cancer cases in the U.S. in 2013 are related to behavioral and lifestyle 
factors such as overweight or obesity, physical inactivity, and poor nutrition.
3
 
 Metabolic syndrome is a cluster of pathophysiological disorders comprising central 
obesity, insulin resistance, hypertension, and dyslipidemia. Based on the application of various 
definitions of metabolic syndrome, an estimated one-third of US adults are afflicted by it.
4
 There 
is substantial evidence that this cluster of metabolic risk factors accelerates onset of 
cardiovascular diseases.
5, 6
 In addition, studies conducted over the past decade indicate that the 
combined metabolic risk factors (MRFs) are positively and significantly associated with overall 
cancer
7
 and site-specific cancers, including breast cancer,
7-20
 digestive cancer,
21
 liver cancer,
14, 22
 
prostate cancer,
23-26
 colorectal cancer,
27-32
 and endometrial cancer.
33
  A recent meta-analysis of 
prospective cohort studies concluded that metabolic syndrome is associated with an elevated 
overall cancer risk among adults.
34
 This study found a significant association between metabolic 
syndrome and increased risk of liver, colorectal, and bladder cancers in men, and endometrial, 
pancreatic, postmenopausal breast, and colorectal cancers in women.
34
 
  Few epidemiologic studies have reported associations between MRFs and age at cancer 
onset. A large cohort study found that obesity in adulthood was linked to increased cancer 
mortality risk.
35
 Overweight and obesity during early adulthood were also associated with earlier 
age at onset in obesity-related cancers, such as pancreatic cancer.
36
 In this large case-control 
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study, obesity from the ages of 20 to 29 years was associated with earlier age of cancer onset by 
seven years.
36
 A nested case-control study suggested hypertensive adults were at risk of 
developing cancer ten years earlier than normotensives.
37
  
  A paucity of literature exists on the association between individual and combined MRFs 
and age at cancer onset. Animal studies suggest that mechanisms, which prevent metabolic 
abnormalities, by reducing serum insulin-like growth factor-1 or androgen concentrations, may 
delay the growth and progression of breast and prostate cancers.
38
 Another animal study found 
that mammary tumors developed earlier in diet-induced obese rats than in lean rats, thus 
supporting the role of hormones and adipokines (produced by adipose tissue) in cell proliferation 
and carcinogenesis.
39
 
 Given  the associations between MRFs and several cancers, as suggested by 
epidemiologic human studies, as well as animal studies, an important research question is 
whether MRFs are associated with earlier age at cancer onset. This question is important for at 
least four reasons. First, age at onset of certain cancers is temporally decreasing. A population-
based study, using data for England and Wales covering the period 1971-1999, found earlier age 
at onset of breast, cervical, and prostate cancer.
40
 Second, earlier cancer onset signifies shorter 
life expectancy, and therefore, major loss of potential years of life.
41
 Third, younger cancer 
patients are likely to have more aggressive cancers, less favorable prognosis, and poorer 
outcomes than older patients.
41-43
 Fourth, earlier age at cancer onset in a family may increase the 
lifetime risk of developing cancer in the next generation.
44, 45
 Therefore, it is important to 
understand the association between metabolic syndrome and age at cancer onset so that 
appropriate guidelines can be developed for cancer screening, prevention, and treatment. 
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 This study assessed the influence of MRFs (obesity, high blood pressure, high total serum 
cholesterol, and diabetes), and their combination, on age at onset of all-site cancer, and cancer of 
the breast, digestive system, and lung.  
4.3 Methods 
4.3.1 Data Source and Study Population: Data were derived from a cohort study, the 
NHANES I Epidemiologic Follow-up Study (NHEFS).
46
 
 
The NHEFS is a national multi-stage, 
stratified probability sample of the non-institutionalized, civilian population in the US. It 
includes participants from the NHANES I cohort, who were ages 25 to 74 years, and completed a 
medical examination at baseline (1971-75).
46
 Participants were followed-up in 1982-84, 1986, 
1987, and 1992. Only 5% of the original NHEFS sample was lost through attrition.
47
  
 Baseline data were acquired by merging five NHANES I data files on anthropometry, 
biochemistry, medical history, medical needs, and medical examination. Since the NHEFS 
follow-up was conducted for participants aged ≥ 25 years and ≤ 74 years at time of NHANES I 
interview, only this group was retained for the analysis. Cancer status was determined by 
merging data from each of the 1982-84, 1986, 1987, and 1992 surveys, in addition to the NHEFS 
vital statistics data. 
 The outcome variable was age at cancer onset. Cancer cases were defined using the 
International Classification of Diseases-9th revision (ICD-9), codes 140-208, excluding ICD-173 
(skin cancer), and were followed up through interview and death certificate data. All the cancer 
cases occurring after the baseline period and reported in 1982-84, 1986, 1987, and 1992 
interviews, were obtained from the first, second and third diagnoses of cancer along with their 
location (cancer-site). Skin cancer cases were not included among total cancer cases since the 
mechanism of skin cancer development is different and does not involve metabolic risk factors. 
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For subjects with multiple cancers, only the first occurring non-skin cancer was included. All 
cancer cases were aligned with year of diagnosis. The final outcome variable, age at cancer 
onset, was computed by subtracting birth year from year of cancer diagnosis, and was computed 
for overall cancer and for cancer of the breast, digestive system, and lung, respectively. 
 A total of 14,407 persons from the NHANES I dataset were followed up in 1982-84. Of 
these, 684 had a cancer diagnosis at baseline (determined from the question "Has a doctor ever 
told you that you have malignant tumor or growth?") or who died within the year of baseline 
interview and were excluded from the analysis. In order to reduce the possibility of reverse 
causation, another 146 who developed cancer in the first two years of the study were excluded 
from analysis. Among those who were followed, 1,837 persons (13.5%) were diagnosed with 
cancer during the study period. Participants with missing data (n = 101) on covariates, which 
were included in the multivariable model, were also excluded from the analysis. The final sample 
was 1,736.  
Information on the following predictor variables was obtained from the baseline 
examination: obesity, assessed as body mass index in kg/m
2
, resting systolic (SBP) and diastolic 
(DBP) blood pressure, measured as continuous variables in mmHg, total serum cholesterol, 
measured as continuous variable in mg/dL, and self-reported diabetes, coded as a dichotomous 
variable. Consistent with American Heart Association guidelines, resting SBP and DBP were 
measured by a physician using a sphygmomanometer at the beginning of the physical 
examination while the subject was in a sitting position.
48
 All of these readings were retrieved 
from the NHANES I medical exam questionnaire. Total serum cholesterol was assessed using a 
semi-automated instrument in the Centers for Disease Control and Prevention's lipid 
standardization laboratory. Information on diabetes was gathered from the NHANES I medical 
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history questionnaire (Has a doctor ever told you had diabetes?) or from the NHANES I 
healthcare needs questionnaire (Did a doctor tell you had diabetes? or, do you take any diabetes 
medicine or insulin?).  
Analyses were adjusted for the following potentially confounding variables: age, race, 
education, family income, physical activity, smoking status, and family history of cancer. The 
baseline medical history questionnaire provided information on age, race, education, family 
income, and physical activity. At baseline, information on smoking status was very limited, and 
information on family history of cancer was not collected. Therefore, information on smoking 
status was combined from the baseline and 1982 surveys, and information on family history of 
cancer was derived from the latter survey.
49-52
  
      4.3.2 Statistical Analysis 
 Multiple linear regression analyses, using the general linear model, were used to assess 
the relationship between MRFs and age at cancer diagnosis.
36, 53
 The severity of multicollinearity 
for each variable was assessed by calculation of the variance inflation factor. All data were 
analyzed using the complex samples module in IBM SPSS Statistics for Windows, version 21.0 
(Armonk, NY: IBM Corp). All analyses incorporated the complex sample design and sample 
weights in order to produce national estimates. 
 The outcome variable, age at cancer onset, was computed by subtracting birth year from 
year of cancer diagnosis, and analyzed as a continuous variable. Metabolic risk factors were 
classified as: (1) obesity: BMI≥ 30 kg/m2; (2) high blood pressure: systolic BP ≥ 140 mm/Hg 
and/or diastolic BP ≥ 90 mm/Hg); (3) high cholesterol: total serum cholesterol ≥ 240 mg/dL; and 
(4) diabetes: presence or absence of diabetes. Multiple linear regression models were used to 
examine the association between MRFs (obesity, high BP, high cholesterol, and diabetes) and 
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age at cancer diagnosis.
36, 53
 The effect of individual MRF was assessed relative to the absence of 
that risk factor. 
 Analyses were adjusted for the following potentially confounding variables: age, race 
(whites versus others), education (high school or less vs. above high school), family income 
(<$5,000, $5,000 to $14,999, and ≥$15,000, based on the poverty line for 1971-75 that was set at 
or below $5,000 as the annual income for a household of four members), physical activity 
(moderately active or very active vs. quite inactive), smoking (smoked 100 cigarettes in one's 
lifetime), and family history of cancer (dichotomous). In the NHANES I dataset, race was 
classified as white, black, or other at baseline. However, for this study, the latter two categories 
were combined and classified as nonwhite due to small number.
50
  
 Age was included in all models as an independent, continuous variable. In addition, 
analyses were further stratified by age categorized as < 50 and ≥ 50 years as at baseline. The 
rationale for this dichotomization was based on previous research that has shown that adults 50 
years or older bear the greatest burden of cancer, with the largest proportions of cancers being 
diagnosed in this age group.
54
 Moreover, there are biological changes, especially in women, 
around age 50. Posthoc, all analyses were also stratified by gender after determining that the 
association between individual MRFs and age at cancer onset differed by gender.
55, 56
 Besides examining the association between individual MRFS and age at cancer onset, 
analyses were performed to assess the combined effect of MRFs on age at cancer onset. An 
additive summary of MRF scores was created by combining the individual MRFs. A score of 
three was assigned to participants with three or four MRFs. The summary score ranged from 0 
(no MRF, the referent category) to 3 (three or four risk factors). Analyses were adjusted for the 
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following potential confounders: age, race, education, family income, physical activity, smoking, 
and family history of cancer, and stratified by gender and age (< 50 and ≥ 50 years of age). 
Site-specific cancers (breast, digestive, and lung cancers) were examined separately in 
evaluating an association between individual MRFs as well as the combined MRF score, and age 
at cancer onset. Cancers of the digestive system included those of the alimentary canal below the 
neck (e.g., esophagus, stomach, small and large intestines) and key digestive organs (i.e., 
pancreas, liver, and gallbladder).  
4.4 Results 
Table 1 presents the baseline characteristics of the study population. Among the 1,736 
persons diagnosed with cancer between 1973 and 1992, approximately half were women and 
most were white. Almost a third of the sample had an annual family income below the poverty 
level, while more than three fourths had a high school education or less. About 17% were obese, 
over half had hypertension, and more than a third had high total cholesterol. Very few 
participants had three or four MRFs. 
Table 2 presents the association between individual MRFs and age at cancer onset among 
males, after adjusting for potential confounders, and stratifying by age and gender. Among males 
less than 50 years of age at baseline, obesity was associated with later age at cancer onset. Mean 
age at cancer onset for obese men who were younger than age 50 was  (mean + SE) 55.8 + 1.52 
years compared to 53.1 + 1.32 years for those who were not obese. Diabetes was associated with 
earlier age at cancer onset in younger males. Mean age at cancer onset for men with diabetes, 
who were younger than age 50, was 52.2 + 2.16 years compared to 56.6 + 1.18 years for those 
who did not have diabetes. Among males 50 years and older, diabetes was again associated with 
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earlier age at cancer onset. Mean age at cancer onset for older men with diabetes was 68.1 + 1.42 
years compared to 70.9 + 0.57 years for those who did not have diabetes.  
Among women 50 years and older, diabetes was associated with earlier age at cancer 
onset (Table 3). Mean age at cancer onset for older women with diabetes was 70.4 + 1.06 years 
compared to 72.4 + 0.81 years for those who did not have diabetes.  
Tables 4 and 5 present the association between the aggregate MRF score (ranging from 1 
MRF to three or four MRFs, compared with the referent category of no MRF) and age at cancer 
onset among males and females, respectively, after adjusting for potential confounders, and 
stratifying by age. No significant association was observed among males Table 4). Among 
women younger than 50 years of age, presence of three or four MRFs was associated with later 
age at cancer onset (Table 5). Mean age at cancer onset for these women was 51.8 + 0.97 years 
compared to 52.7 + 0.98 years for those who had no MRF. This association reversed in older 
women. Presence of three or four MRFs in women 50 and older was associated with earlier age 
at cancer onset. Mean age at cancer onset for older women with combined MRFs was 70.2 + 
0.89 years compared to 72.9 + 1.03 years for those who had no MRF. 
Table 6 presents the associations between individual MRFs and age at breast cancer onset 
in all women, and in postmenopausal women. Diabetes was associated with earlier age at 
postmenopausal breast cancer onset. Mean age at onset was 66.0 + 1.46 years compared to 68.7 
+ 0.74 years for those who did not have diabetes. Presence of combined three or four MRFs was 
associated with earlier age at onset among all women and postmenopausal women (Table 7). 
Mean age at cancer onset for all women with combined MRFs was 59.1 + 1.22 years compared 
to 62.4 + 1.08 years for those who had no MRF. Among postmenopausal women with combined 
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MRFs, mean age at cancer onset was 67.0 + 1.07 years compared to 70.9 + 1.52 years for those 
who had no MRF.  
Table 8 presents the associations between individual MRFs and age at digestive cancer 
onset among males and females. No association was observed in any strata. Examining the 
combined MRFs, presence of one, three or four MRFs was associated with earlier age at 
digestive cancer onset among females (Table 9). Mean age at onset among females with three or 
four MRFs was 68.5 + 1.25 years compared to 72.9 + 1.19 years for those who did not have any 
MRF.  
Table 10 presents the association between individual MRFs and age at lung cancer onset 
among males and females. Overall, diabetes was associated with earlier age at onset among both 
males and females. Mean age at lung cancer onset for males with diabetes was 58.7 + 1.77 years 
compared to 66.1 + 0.90 years for those who did not have diabetes. Similarly, mean age at lung 
cancer onset for females with diabetes was 62.9 + 1.78 years compared to 67.5 + 1.05 years for 
those who did not have diabetes. When examining the combined MRFs, presence of three or four 
MRFs in males was also associated with earlier age at lung cancer onset (Table 11). Mean age at 
onset among males with three or four MRFs was 62.5 + 1.57 years compared to 66.2 + 1.25 
years for those who did not have any MRF.  
4.5 Discussion 
 The aim of this study was to examine whether MRFs and their combination were 
associated with age at cancer onset. Since there are several definitions of metabolic syndrome, 
and thus several possible combinations, the independent effect of each single component was 
also examined. 
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 Study results show an increased risk of diabetes associated with earlier age at cancer 
onset in younger and older males, and in older females. Diabetes was also associated with early 
age at onset of postmenopausal breast cancer, and lung cancer in both genders. Epidemiologic 
reviews and meta-analytic studies suggest that people with diabetes were at a higher risk for 
overall cancer and cancers of several sites, such as liver, pancreas, endometrium, colon, rectum, 
breast, and bladder.
57, 58
  Although several observational studies do not show an association 
between diabetes and lung cancer, the Metabolic Syndrome and Cancer project that comprises 
six large prospective cohorts found that a one millimole per liter increase in glucose levels in 
men was associated with increased risk for incidence and mortality from cancer of lung, trachea, 
and bronchus.
59
 Another cohort study found an increased risk for lung cancer mortality in 
diabetic women.
60
 
Study results also show that obesity was associated with later age at cancer onset in males 
less than 50 years of age. While epidemiologic evidence suggests obesity is associated with an 
increased risk of cancer in men,
61
 studies on the association between obesity and age at cancer 
onset are scant.  
Presence of a combination of three or four MRFs was associated with later age at cancer 
onset among females less than 50 years of age. This association was reversed in older women. 
Presence of three or four MRFs was associated with earlier age at onset of: (a) overall cancer in 
women 50 and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, and (d) 
lung cancer in males. A meta-analysis found that metabolic syndrome was positively associated 
with postmenopausal breast, endometrial, pancreatic, and colorectal cancers in women.
34
 A large 
cohort study showed that metabolic syndrome was associated with increased liver and breast 
cancer risk in women.
14
 Another cohort study concluded with a significant increase in breast 
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cancer risk among older women with two or three MRFs, suggesting  that the combined MRFs 
may elevate breast cancer risk beyond a single MRF, such as obesity.
62
 However, studies on the 
association between combined MRFs and age at cancer onset are lacking. 
Studies have suggested potential biological mechanisms that link MRFs with various 
cancers. In brief, through various mechanisms, including obesity, increased inflammatory 
markers such as tumor necrosis factor - and interleuken-6, increased adipokines such as leptin 
and decreased adiponectin, increased levels of free fatty acids and triglycerides, insulin 
resistance, increased insulin-like growth factor-1, and increased oxidative stress, MRFs have 
been shown to cause angiogenesis, cell migration, mitogenesis, and DNA damage.
63
 There is, 
therefore, an emerging hypothesis that a combination of MRFs may be an important etiologic 
factor for the onset of cancer.
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Gender differences in the association between MRFs and cancer can arise for several 
reasons. Components of metabolic syndrome operate differently by gender.
55, 56
 Metabolic 
hormones that control cell growth can elevate cancer risk in women, whereas obesity-related 
hyperinsulinemia can increase the risk in men.
65
 Longitudinal studies show that the association 
between metabolic syndrome and elevated cancer risk is stronger in women.
14
 Animal studies 
have shown that obesity-related adipokines enhance cell proliferation and elevate breast cancer 
risk.
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The current study has several potential limitations. For example, blood glucose levels 
were not measured directly but rather, a self-reported diagnosis of diabetes was used as an 
indicator of high levels. In addition, while total serum cholesterol levels were measured directly 
and not self-reported, there were no separate measures for triglycerides, or low and high-density 
lipoprotein cholesterol levels (LDL and HDL). This may be important since previous research 
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has shown that high HDL may be inversely associated with site-specific and overall cancer,
67
 
although others reported no association between triglyceride or HDL levels and such site-specific 
cancers as colorectal cancer.
32
 
Prior research has reported differences in age at cancer onset among different 
racial/ethnic populations for overall and site-specific cancers.
68, 69
 However, while models were 
adjusted for race, a stratified analysis could not be performed due to the small sample size for 
races other than white. For this reason, nonwhite were combined into one category, although 
studies show racial differences related to MRFs.
70
  
  This study has several strengths. For example, data for this study were derived from a 
longitudinal cohort study design with high follow-up rates. Specifically, 96% of the study 
population was successfully traced at some point through the 1992 follow-up.
47
 It is a large 
nationally representative sample of the US population. In addition, self-report bias tended to be 
minimized because MRFs, such as total serum cholesterol, as well as blood pressure and 
anthropometry (BMI), were based on body measurements and laboratory data. All analyses 
utilized complex sample survey design for results representative of the population. 
In conclusion, diabetes and a combination of three or four MRFs were found to be 
associated with earlier age at onset of overall and site-specific cancers. The association with 
combined MRFs was stronger in women. Future research needs to determine the underlying 
mechanisms that predispose people with metabolic abnormalities to cancer. To this end, it is 
essential to examine the relationship among site-specific cancers, stratified by gender and race, 
with detailed information on LDL and HDL cholesterol levels, abdominal and visceral adiposity, 
blood glucose levels, time period of each abnormality, and medications and their period of use. 
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5.1 Discussion 
 The three dissertation studies were conducted with the overall goal of examining the 
association between individual and combined metabolic risk factors (MRFs) and subsequent risk 
of overall and site-specific cancers of the breast, digestive system, and lung. This chapter 
discusses the findings from the three studies, lists their strengths and limitations, and concludes 
with a suggested future course of action. 
5.2 Study 1 Discussion: Metabolic Syndrome is associated with increased breast cancer 
risk: A systematic review with meta-analysis 
 The purpose of this aggregate data meta-analysis was to examine the association between 
metabolic syndrome and the risk for breast cancer in adult females. Of the 291 studies screened, 
47 underwent a full-text review, of which eight studies with nine independent cohorts met the 
eligibility criteria. The overall results of this aggregate data meta-analysis show a modest 
positive association between metabolic syndrome and breast cancer risk in adult females, with a 
47% elevated risk for incident breast cancer for adult females with metabolic syndrome.  
 This finding is strengthened by the robustness of results from other analyses. These 
include: (1) examination for publication bias, (2) influence analysis with each study deleted from 
the model once, (3) deletion of the two case-control studies with odds ratios from the overall 
model, (4) limiting the analysis to prospective designs, (5) restricting the study to only 
postmenopausal women in the analysis, and (6) limiting the results to studies that controlled for 
four or more of the important confounders. 
 Risk of bias was low for a majority of studies with respect to study design, cancer 
assessment, and sample size; but it was high or unclear for a majority of them concerning the 
handling of missing data and non-participation of subjects at each stage of follow-up. This risk 
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was higher in case-control and retrospective cohort study designs compared with prospective 
cohort study designs. The association between metabolic syndrome and breast cancer risk was 
stronger when limited to postmenopausal women. These findings are supported by the recent 
meta-analysis on metabolic syndrome and breast cancer risk in postmenopausal women.
1
 
 The current meta-analysis identified some of the methodological challenges when 
pooling results from various studies examining the association between metabolic syndrome and 
breast cancer risk. These include (1) the different methods used to assess exposure, identify 
cancer, control for confounders, and define metabolic syndrome, (2) limiting studies to those 
published in English, which may have led to inflated results, (3) the relatively small number of 
studies that met the inclusion criteria, (4) the inability of a few studies to provide raw data for 
calculating the risk estimates, (5) the different study designs employed, and (6) the varied 
populations studied.  
 This study has several strengths. First, to the best of my knowledge, this is the first 
systematic review and meta-analysis to examine the association between metabolic syndrome 
and breast cancer risk in all adult women, with a sub-analysis of post-menopausal women. 
Second, all included studies were longitudinal, reported the results of multivariable analyses, and 
in eight of the nine cohorts, breast cancer was objectively determined. Third, with robust results, 
tested after conducting several analyses, the findings provide direction for future. 
 In conclusion, the overall results of this meta-analysis suggest that there is a modest 
positive association between MS and risk of breast cancer in adult females.  
5.3 Study 2 Discussion: Association between individual and combined metabolic risk 
factors and cancer risk  
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 The aim of this study was to examine whether MRFs, either individually or in 
combination, were associated with the risk of overall and selected site-specific cancers of the 
breast, digestive system, and lung. The overall results from this large, prospective cohort study 
showed that diabetes, high BP, and the presence of a combination of three or four MRFs were 
associated with higher breast cancer risk among postmenopausal women. Obesity in males less 
than 50 elevated the risk of digestive cancer. 
 Epidemiologic evidence points toward increased risk of breast cancer in postmenopausal 
diabetic women.
1, 2
 Diabetes is frequently associated with insulin resistance, increased 
circulating concentrations of insulin, and insulin-like growth factors. Studies have shown insulin 
has mitogenic effects on breast tissue.
3
 In addition, insulin inhibits the production of sex 
hormone-binding globulin, resulting in an increase in bioavailable estradiol.
4
 Increased estradiol 
levels have been associated with the risk of developing breast cancer.
5
  
 The finding that postmenopausal women with high BP were at an increased risk of breast 
cancer  is also supported by the recent meta-analysis on breast cancer risk in postmenopausal 
women.
1
 Cancer and hypertension are both characterized by the proliferation of smooth muscle 
cells.
6
 Another hypothesis indicates abnormalities
 
of carcinogen binding to DNA in lymphocytes 
of hypertensive
 
women.
7
 
 Study results showing an association between a combination of  three or four MRFs and a 
higher risk of postmenopausal breast cancer, are supported by findings from a recent meta-
analysis, suggesting that the increased risk for postmenopausal breast cancer was greater from 
the combined effect of MRFs than from individual MRFs.
1
 A combination of MRFs may activate 
different molecular pathways through metabolic, endocrine, and immune cell changes, which can 
result in breast tumorigenesis.
8
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 Among men, the only significant association observed was that of obesity with elevated 
risk of digestive cancer. Other studies have also observed a similar association between 
overweight/ obesity and digestive cancers, such as pancreatic
9, 10
 and colorectal
11
 cancers in men. 
Current study has certain potential limitations. For example, blood glucose levels were 
self-reported. There were no separate measures for triglycerides, or low and high-density 
lipoprotein cholesterol levels (LDL and HDL). A stratified analysis could not be performed due 
to small sample size for races other than white, and nonwhite had to be combined into one 
category. Analyses on digestive and lung cancer could not be stratified by age because of small 
number of cancer cases. 
  This study has several strengths. For example, data were derived using a strong 
longitudinal cohort study design with high follow-up rates. In addition, self-report bias tended to 
be minimized by measuring serum total cholesterol as well as blood pressure and anthropometry 
(body mass index).  
5.4 Study 3 Discussion: Association between metabolic risk factors and age at cancer 
onset 
 The aim of this study was to examine whether MRFs, either individually or in 
combination, were associated with age at onset of all-site cancer, and cancer of the breast, 
digestive system, and lung, respectively. 
 Study results showed an increased risk of diabetes associated with earlier age at cancer 
onset in younger and older males, and in older females. Diabetes was also associated with earlier 
age at onset of postmenopausal breast cancer, and lung cancer in both genders. Presence of a 
combination of three or four MRFs was associated with earlier age at onset of: (a) overall cancer 
85 
 
in women 50 years and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, 
and (d) lung cancer in males. 
 Epidemiologic studies show an association between individual and combined MRFs and 
elevated cancer risk. However, there are very few studies on the association of these risk factors 
with age at cancer onset. Epidemiologic reviews and meta-analytic studies show people with 
diabetes were at a higher risk for overall cancer and cancers of several sites, such as liver, 
pancreas, endometrium, colon, rectum, breast, and bladder.
5, 12
 The Metabolic Syndrome and 
Cancer project that comprises six large prospective cohorts found an association between 
increasing levels of glucose and increased risk for incidence and mortality from cancer of lung, 
trachea, and bronchus in men.
13
 Another cohort study found an increased risk for lung cancer 
mortality in diabetic women.
14
 
Study results show earlier age at cancer onset among older women with a combination of 
three or four MRFs. This finding is supported in the literature. A meta-analysis found that 
metabolic syndrome was positively associated with postmenopausal breast, endometrial, 
pancreatic, and colorectal cancers in women.
15
 A large cohort study showed that metabolic 
syndrome was associated with increased liver and breast cancer risk in women.
16
 Another cohort 
study concluded with a significant increase in breast cancer risk among older women with two or 
three MRFs, suggesting  that the combined MRFs may elevate breast cancer risk beyond a single 
MRF, such as obesity.
17
 However, studies on the association between combined MRFs and age 
at cancer onset are lacking. 
Studies have suggested potential biological mechanisms that link MRFs with various 
cancers. In brief, through various mechanisms, including obesity, increased inflammatory 
markers such as tumor necrosis factor - and interleuken-6, increased adipokines such as leptin, 
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decreased adiponectin, increased levels of free fatty acids and triglycerides, insulin resistance, 
increased insulin-like growth factor-1, and increased oxidative stress, MRFs have been shown to 
cause angiogenesis, cell migration, mitogenesis, and DNA damage.
18
 There is, therefore, an 
emerging hypothesis that a combination of MRFs may be an important etiologic factor for the 
onset of cancer.
19
 
 This study shares similar strengths and limitations as those from the previous study. 
Some of the potential limitations include self-reported diabetes diagnosis, no separate measures 
for triglycerides, or low and high-density lipoprotein cholesterol levels, and small sample size for 
races other than white. The study has strengths that include a longitudinal cohort study design 
with high follow-up rates, and MRFs, such as total serum cholesterol as well as blood pressure 
and anthropometry (body mass index) based on body measurements and laboratory data. More 
importantly, there is very little research conducted on this subject. 
5.5 Conclusion 
 The prevalence of MRFs, individually and in the aggregate, is growing rapidly.
20
 There is 
limited biologic and epidemiologic evidence indicating an association between MRFs and 
cancer. The goal of this dissertation was to examine the association between individual and 
combined MRFs with subsequent risk of overall and site-specific cancers of the breast, digestive 
system, and lung. Results from the meta-analysis show that the combined MRFs (metabolic 
syndrome) are modestly associated with an increased risk for breast cancer in all adult women. 
Results from the association between individual and combined MRFs showed that diabetes, high 
BP, and the presence of a combination of three or four MRFs were associated with higher breast 
cancer risk among postmenopausal women. Diabetes was also associated with earlier age at (a) 
cancer onset in younger and older males, (b) cancer onset in older females, (c) postmenopausal 
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breast cancer onset, and (d) lung cancer onset in both genders. Lastly, presence of a combination 
of three or four MRFs was associated with earlier age at onset of: (a) overall cancer in women 50 
and older, (b) postmenopausal breast cancer, (c) digestive cancer in females, and (d) lung cancer 
in males. 
 In conclusion, study results suggest that diabetes and metabolic syndrome (or a 
combination of MRFs) may serve as markers for postmenopausal breast cancer risk, but not for 
overall or any other site-specific cancer risk. The association between diabetes and a 
combination of three or four MRFs and earlier age at onset was observed not only for 
postmenopausal breast cancer, but also for overall cancer in women 50 and older, digestive 
cancer in women, and lung cancer in males. 
 Future research needs to determine the underlying mechanisms that may predispose 
people with metabolic abnormalities to cancer. To this end, it is essential to examine the 
relationship among site-specific cancers, stratified by age, gender and race, with detailed 
information on triglycerides, low and high-density lipoprotein cholesterol levels, abdominal and 
visceral adiposity, blood glucose levels, duration of each abnormality, and medications and their 
period of use. 
 The positive association of a combination of MRFs with breast cancer in the meta-
analysis points toward the need to develop public health strategies to manage these risk factors. 
Diabetes may also serve as a marker for postmenopausal breast cancer risk. Given the 
increasingly large global burden of metabolic risk factors, even a small association with breast 
cancer can have a substantial public health impact. Risk assessment tools can be developed that 
incorporate MRFs as a risk factor for breast cancer. Healthcare providers will then be better 
equipped to identify high-risk women for primary and secondary prevention. 
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APPENDIX  A
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Appendix A: Table 1. Criteria for Risk of Bias Assessment. 
Criteria Low Risk High Risk Unclear Risk 
Study design Prospective or retrospective cohort, 
nested case-control 
Case-control Information not 
reported 
Adjustment of confounders Adjusted for 4 or more of the 
following: age, education/income, 
family history of cancer, hormone 
therapy use/oral contraceptive 
use/reproductive history, smoking 
status, and alcohol consumption 
Adjusted for 3 or less of the following: 
age, education/income, family history 
of cancer, hormone therapy use/oral 
contraceptive use/reproductive history, 
smoking status, and alcohol 
consumption 
Information not 
reported 
Selection of participants and 
their eligibility criteria 
Studies clearly stating their eligibility 
criteria and the sources and methods of 
selection of participants 
Studies not clearly stating their 
eligibility criteria and the sources and 
methods of selection of participants 
Information not 
reported 
Measurement of predictor 
variables 
Identified through objective measures Self-reported or pharmaceutical 
prescriptions 
Information not 
reported 
Breast cancer diagnosis Histologically confirmed or identified 
through cancer registry/ medical 
records 
Self-reported Information not 
reported 
Study size Large enough for adequate power Not large enough for adequate power Information not 
reported 
Handling of missing data Missing data analysis specified Missing data deleted from analysis Information not 
reported 
Reasons for non-
participation of individuals 
at each stage of the study 
Reasons clearly reported for each stage 
of study 
Reasons not reported for each stage of 
study 
Information not 
reported 
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Appendix A: Table 2. Characteristics of Studies. 
 
Author Year Country Study 
Design 
Sample 
Size  
Baseline 
Year 
Follow-
up 
Years 
Age Breast 
Cancer 
Cases 
Menopausal 
Status 
Statistic  
Agnoli et al.
43
  2010 Italy Prospective 
nested case-
control 
792 1987-92 2003 35-69 163 Post Rate ratios 
Bosco
61
 2011 USA Prospective 
cohort 
49,172 1995 2007 21-69 1228 Mixed, post Incidence rate 
ratios 
Inoue et al.
62
  2009 Japan Prospective 
cohort 
18,176 1990-94 2004 40-69 120 Mixed, post Hazard ratios 
Kabat et al.
48
  2009 USA Prospective 
cohort 
4,888 1993-98 2005 50-79 165 Post Hazard ratios 
Osaki et al.
13
  2012 Japan Retrospectiv
e cohort 
15,386 1992-
2000 
2007 20+ 77 Mixed, post Hazard ratios 
Ronco et al.
51
  2012 Uruguay Case-control 912 2004 2009 <70 367 Post Odds ratios 
Rosato et al. -  
Cohort I
14
 
2011 Italy Case-control 3,858 1983 1994 33-86 1,988 Post Odds ratios 
Rosato et al.-  
Cohort II
14
 
2011 Italy and 
Switzerland 
Case-control 4,093 1991 2007 33-79 1,881 Post Odds ratios 
Russo et al.
63
 2008 Italy Prospective 
cohort 
Not 
reported 
1999 2005 ≥40 99 Mixed Standardized 
incidence 
ratios 
Note: Citations for the included studies are in the reference section of  Chapter 2, pages 28-36. 
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Appendix A: Table 2 (continued).  
Author Exposure Assessment Cancer Identification Confounders 
Agnoli et al.
43
  Questionnaire, 
anthropometric measures, 
fasting blood draw 
Cancer registry age, age at menarche, age at first birth, years from 
menopause, number of full-term pregnancies, oral 
contraceptives, hormone therapy, education, cancer in first 
degree relatives, breastfeeding, smoking, alcohol 
consumption 
Bosco
61
 Questionnaire Medical records or 
cancer registry data 
age, education, BMI at 18, vigorous activity 
Inoue et al.
62
  Questionnaire, 
anthropometric measures, 
fasting and non-fasting 
blood draw 
Self-report age, study area, smoking status, ethanol intake, physical 
activity, total cholesterol 
Kabat et al.
48
  Questionnaire, 
anthropometric measures, 
fasting blood draw 
Self-report  confirmed 
by medical records 
and tumor registry 
abstracts 
age, education, ethnicity, BMI, oral contraceptive use, 
postmenopausal hormone therapy,  age at menarche, age at 
first birth, age at menopause, alcohol, family history of breast 
cancer, history of breast biopsy, physical activity, energy 
intake, smoking status 
Osaki et al.
13
  Questionnaire, 
anthropometric measures, 
fasting blood draw 
Cancer registry age, smoking, heavy drinking 
Ronco et al.
51
  Questionnaire, 
anthropometric measures 
after cancer 
Histologically 
confirmed breast 
cancer 
age, residence, age at menarche, parity, age at first live birth, 
months of breastfeeding, use of oral contraceptives, BMI, 
menopausal status, family history of BC, and intake of beef, 
tomatoes and oranges 
Rosato et al.
14
  Questionnaire, waist 
circumference measure 
Histologically 
confirmed breast 
cancer 
age, study center, study period, education, alcohol 
consumption, age at menarche, parity and age at first birth, 
age at menopause, hormone replacement therapy use, family 
history of breast cancer 
Russo et al.
63
  Pharmaceutical 
prescriptions for MS 
Cancer registry Not reported 
Note: Citations for the included studies are in the reference section of  Chapter 2, pages 28-36. 
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Appendix A: Table 3. Definitions and Criteria for Metabolic Syndrome in the Included Studies. 
 
Agnoli et al.
43
  2 definitions (≥ 3 of the following components): 
1. Highest or lowest (HDL-C) tertiles in controls: WC > 86 cm; Triglycerides > 126 mg/dL; HDL-C ≤= 55 
mg/dL; Fasting Glucose > 88 mg/dL (or previously diagnosed T2DM); Mean BP ≥ 106.5 mmHg (or 
treatment for previously diagnosed HTN).  
2. NCEP: WC > 88 cm; Triglycerides ≥150 mg/dL; HDL-C < 50 mg/dL; SBP ≥130 mmHg or Diastolic BP 
≥ 85 mmHg; Fasting Glucose ≥ 110 mg/dL.  
Bosco
61
  ≥ 3 of the following components: WC ≥ 88 cm; T2DM self-reported diagnosis at ≥ 30 years at baseline; 
HTN self-reported diagnosis plus diuretics or hypertensive medication use at baseline; Cholesterol self-
reported diagnosis of high cholesterol and cholesterol-lowering medication at baseline. 
Inoue et al.
62
  2 definitions:  
1. Grundy (NHLBI 2005): Any 3 or more: BMI ≥ 25 kg/m2; HTN ≥130/85 mmHg or medication use; 
Glucose ≥ 100 mg/dL fasting or 140 mg/dL non-fasting or on treatment; low HDL-C < 50 mg/dL; 
Triglycerides ≥150 mg/dL,;  
2. IDF: overweight and at least 2 other components. 
Kabat et al.
48
  ATP III modified to exclude those with Glucose ≥ 126 mg/dL or those taking diabetic medication 
Osaki et al.
13
  6 definitions: Japan 2005, Modified NCEP 2001, Modified NCEP 2004, Modified IDF 2006, Modified 
WHO 1999, NCEP 2001 with BP 140/90 
Ronco et al.
51
  2 definitions:  
1. Diabetes+Overweight+HTN 
2. Diabetes+Overweight+Dyslipidemia 
Rosato et al.
14
  Combined presence of diabetes, drug-treated HTN, drug-treated hyperlipidemia (as a proxy indicator of 
elevated Triglycerides and reduced HDL-C), WC ≥ 88 cm or BMI ≥30 kg/m2 when WC was missing 
Russo et al.
63
  Pharmacological definition - who chronically received antihypertensive, glucose-lowering, and lipid 
modifying drugs 
Notes: BMI = Body Mass Index; BP = Blood Pressure; HDL-C = High Density Lipoprotein Cholesterol; HTN = Hypertension; WC = 
Waist circumference; IDF = International Diabetes Federation; NCEP ATP III = National Cholesterol Education Program's Adult 
Treatment Panel III; NHLBI = National Heart, Lung, and Blood Institute; WHO = World Health Organization. 
 
Note: Citations for the included studies are in the reference section of  Chapter 2, pages 28-36. 
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Appendix A: Table 4. Study-Level Results for Risk of Bias Assessment. 
Methods 
Agnoli 
et al.
43
  
Bosco
61
 Inoue 
et al.
62
  
Kabat 
et al.
48
  
Osaki 
et al.
13
  
Ronco 
et al.
51
  
Rosato 
et al.
14
  
Russo et 
al.
63
  
Study design Low Low Low Low Low High High Low 
Variables (confounders) Low High High Low High Low Low Unclear 
Participants (eligibility, selection) Low Low Low Low Low Low Low Low 
Data sources/ predictor measurement Low High Low Low Low High High High 
Data sources/ outcome measurement Low Low High Low Low Low Low Low 
Study size (adequate power) Low Low Low Low Low Low Low Low 
Missing data analysis High High High Low High Low Unclear Unclear 
Results 
        Participants (non-participation) High High High High Low Low High High 
         Note: Citations for the included studies are in the reference section of  Chapter 2, pages 28-36. 
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Figure 1. Flow diagram describing the selection of studies.  
*CINAHL: Cumulated Index to Nursing and Allied Health Literature. 
Records after duplicates 
removed (n = 291) 
Initial records screened based 
on title and abstracts (n = 291) 
Full-text articles assessed for 
eligibility (n = 47) 
Articles included in meta-
analysis (n = 8), 9 independent 
cohorts 
Reasons for excluding records after full-text review (n=39) 
• Individual metabolic syndrome components (not combined 
syndrome) (n = 13) 
• Not original epidemiological study (n = 7) 
• Review articles (n = 7) 
• Breast cancer patients only (n = 5)  
• Cross-sectional study (n = 4) 
• MS measured as added individual z-scores (n = 1) 
• Not breast cancer (n = 2) 
Reason for excluding records on first screening: Predictor and/or 
outcome not reported (n = 244) 
Initial records identified = 401 
Web of Science (n = 295) 
PubMed (n = 79) 
CINAHL* (n = 15) 
ProQuest (n = 12) 
Cross-referencing (n = 0) 
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Study name Statistics for each study Risk ratio and 95% CI
Risk Lower Upper 
ratio limit limit
Agnoli, 2010 1.58 1.07 2.33
Bosco, 2011 1.14 0.79 1.64
Inoue, 2009 0.82 0.50 1.35
Kabat, 2009 1.12 0.78 1.61
Osaki, 2012 2.87 1.67 4.94
Ronco, 2012 5.79 1.52 22.03
Rosato-I, 2011 1.76 1.03 3.01
Rosato-II, 2011 1.87 1.42 2.47
Russo, 2008 1.17 0.95 1.44
1.47 1.15 1.87
0.1 0.2 0.5 1 2 5 10
Reduced Risk Increased Risk
 
Figure 2. Forest plot for metabolic syndrome and breast cancer risk (random-effects model).  
The black circles represent the weighted risk ratio (RR) for each result from each study while the horizontal lines represent the lower and 
upper 95% confidence intervals (CI) for the RR. The black diamond represents the overall pooled RR while the left and right sides of the 
diamond represent the lower and upper 95% CI for the pooled RR. For studies that included more than one definition of metabolic syndrome, 
the following were used: Agnoli et al. (tertile definition), Bosco (time-independent definition), Osaki et al. (modified NCEP 2001 definition), 
Ronco et al. (diabetes, overweight and hypertension definition).  
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Figure 3. Funnel plot and Trim and Fill procedure for assessing publication bias.  
The white circles represent the log risk ratios (LRR) for each result from each study while the black circles represent the imputed LRR (n = 
2). The white diamond represents the pooled LRR while the black diamond represents the pooled LRR, including the two imputed values. 
The left and right sides of each diamond represent the lower and upper 95% confidence intervals. For those studies that included more than 
one definition of metabolic syndrome, the following were used: Agnoli et al. (tertile definition), Bosco (time independent definition), Osaki 
et al. (modified NCEP 2001 definition), and Ronco et al. (diabetes, overweight and hypertension definition). 
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Study name Statistics with study removed Risk ratio (95% CI) with study removed
Lower Upper 
Point limit limit
Osaki, 2012 1.36 1.09 1.70
Rosato-II, 2011 1.41 1.09 1.82
Ronco, 2012 1.41 1.12 1.77
Rosato-I, 2011 1.44 1.11 1.88
Agnoli, 2010 1.46 1.11 1.92
Bosco, 2011 1.53 1.17 2.01
Kabat, 2009 1.54 1.17 2.01
Russo, 2008 1.54 1.16 2.05
Inoue, 2009 1.56 1.22 1.99
1.47 1.15 1.87
0.1 0.2 0.5 1 2 5 10
Reduced Risk Increased Risk
 
 
Figure 4. Influence analysis with each result from each study deleted from the random-effects model once.  
The black circles represent the risk ratio (RR) for each result from each study while the horizontal lines represent the lower and upper 95% 
confidence interval (CI) for the RR. The black diamond represents the overall pooled result while the left and right sides of the diamond 
represent the lower and upper 95% CI for the pooled RR. For studies that included more than one definition of metabolic syndrome, the 
following were used: Agnoli et al. (tertile definition), Bosco (time-independent definition), Osaki et al. (modified NCEP 2001 definition), 
and Ronco et al. (diabetes, overweight and hypertension definition). 
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Study name Cumulative statistics Cumulative risk ratio (95% CI)
Lower Upper 
Point limit limit
Russo, 2008 1.17 0.95 1.44
Inoue, 2009 1.06 0.77 1.45
Kabat, 2009 1.11 0.94 1.32
Agnoli, 2010 1.17 0.96 1.44
Bosco, 2011 1.17 1.01 1.36
Rosato-I, 2011 1.21 1.03 1.43
Rosato-II, 2011 1.31 1.07 1.61
Osaki, 2012 1.41 1.12 1.77
Ronco, 2012 1.47 1.15 1.87
1.47 1.15 1.87
0.5 1 2
Reduced Risk Increased Risk
Figure 5. Cumulative meta-analysis, ranked by year and based on a random-effects model.  
The black circles represent the cumulative risk ratios (RR) for each result from each study while the horizontal lines represent the lower and 
upper 95% confidence intervals for the RR. The black diamond represents the overall pooled RR while the left and right sides of the diamond 
represent the lower and upper 95% confidence intervals for the pooled RR. For those studies that included more than one definition of 
metabolic syndrome, the following were used: Agnoli et al. (tertile definition), Bosco (time independent definition), Osaki et al. (modified 
NCEP 2001 definition), and Ronco et al. (diabetes, overweight and hypertension definition).  
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Appendix B: Association between metabolic risk factors and cancer risk 
Table 1: Characteristics of the Study Population, National Health and Nutrition 
Examination Survey I  (NHANES I) Epidemiologic Follow-up Study, 1971-1992 
(Unweighted sample size = 10,694 ) 
 
Characteristics of the study 
population 
Total % Mean (SE) 
Age at baseline (years)   48.78 (0.15) 
Women 6339 59.3  
Men 4355 40.7  
Race/ethnicity    
    White 9125 85.3  
    Non-white 1569 14.7  
Family income    
    Below $5,000 2794 26.1  
    $5,001 - $15,000 5558 52.0  
    Above $15,000 2342 21.9  
Education    
    High school or less 8159 76.3  
    Above high school 2535 23.7  
Physical activity    
    Moderately or very active 9652 90.3  
    Quite inactive 1042 9.7  
Smoked 100 cigarettes in lifetime    
    Yes 5786 54.1  
    No 4477 41.9  
    Missing 431 4.0  
Family history of cancer    
    Yes 3763 35.2  
    No 6006 56.2  
    Missing 925 8.6  
BMI,  kg/m
2
   25.68 (0.05) 
BMI categories    
    Underweight 333 3.1  
    Healthy weight 5020 46.9  
    Overweight 3562 33.3  
    Obese 1779 16.6  
Blood pressure     
    High BP 4851 45.4  
    No high BP  5843 54.6  
    Diastolic (mmHg)   83.54 (0.13) 
    Systolic (mmHg)   134.03 (0.23) 
               Continued... 
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Serum cholesterol (mg/dL)   220.82 (0.47) 
    High (>=240 mg/dL) 3383 31.6  
    Not high cholesterol 7311 68.4  
Diabetes    
    Yes 518 4.8  
    No 7969 74.5  
    Missing 2207 20.6  
Metabolic Risk Factor (MRF)    
    MRF 0 3031 28.3  
    MRF 1 2925 27.4  
    MRF 2 1924 18.0  
    MRF 3 or 4 607 5.7  
    Missing 2322 21.7  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; MRF, Metabolic Risk Factor; 
SE, Standard Error.
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Table 2: Association between Individual Metabolic Risk Factors and Cancer Risk among Males 
 
Age <50 Years (n =  1972, Cancer cases = 140) Age ≥ 50 Years (n = 2383, Cancer cases = 691) 
Variable Cancer cases Sample size 
Hazard ratio
a 
 
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
 
(95% CI) 
BMI≥30 18 244 1.00 (0.57, 1.76) 89 323 1.08 (0.81, 1.46) 
BMI<30 122 1728 Referent 602 2060 Referent 
 High BP 56 741 0.89 (0.63, 1.25) 398 1498 0.84 (0.68, 1.05) 
< High BP 84 1231 Referent 293 885 Referent 
Cholesterol≥240 44 484 1.21 (0.85, 1.72) 232 855 1.00 (0.81, 1.23) 
Cholesterol<240 96 1488 Referent 459 1528 Referent 
Diabetes 4 37 1.02 (0.32, 3.29) 34 175 1.05 (0.60, 1.84) 
No Diabetes 102 1350 Referent 524 1794 Referent 
Missing 34 585 
 
133 414  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 3: Association between Individual Metabolic Risk Factors and Cancer Risk among Females 
 
Age <50 Years (n = 3722, Cancer cases = 364) Age ≥ 50 Years (n = 2617, Cancer cases = 572) 
Variable Cancer cases Sample size 
Hazard ratio
a 
 
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
 
(95% CI) 
BMI≥30 70 575 1.18 (0.80, 1.74) 129 637 0.74 (0.54, 0.99) 
BMI<30 294 3147 Referent 443 1980 Referent 
 High BP 96 843 1.02 (0.71, 1.46) 375 1769 0.97 (0.78, 1.21) 
< High BP 268 2879 Referent 197 848 Referent 
Cholesterol≥240 83 617 1.20 (0.89, 1.61) 322 1427 1.27 (1.01, 1.58) 
Cholesterol<240 281 3105 Referent 250 1190 Referent 
Diabetes 10 72 0.91 (0.38, 2.17) 39 234 1.12 (0.70, 1.78) 
No Diabetes 293 2898 Referent 441 1927 Referent 
Missing 61 752 
 
92 456  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 4: Association between Combined Metabolic Risk Factors Score and Cancer Risk among Males 
 
Age <50 Years (n = 1987, Cancer cases = 141) Age ≥ 50 Years (n =2396, Cancer cases = 692) 
Variable Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
MRF 3 or 4 5 53 1.09 (0.40, 2.98) 23 120 0.63 (0.35, 1.12) 
MRF 2 21 205 1.11 (0.68, 1.80) 148 591 0.81 (0.59, 1.12) 
MRF 1 37 501 0.92 (0.55, 1.55) 250 850 0.93 (0.67, 1.28) 
MRF 0 43 628 Referent 137 408 Referent 
Missing 35 600  134 
427  
 
Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor. 
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 5: Association between Combined Metabolic Risk Factors Score and Cancer Risk among Females 
 
Age <50 Years (n = 3773, Cancer cases = 371) Age ≥ 50 Years (n = 2653, Cancer cases = 580) 
Variable Sample size Cancer cases 
Hazard ratio
a
  
(95% CI) 
Sample size Cancer cases 
Hazard ratio
a
  
(95% CI) 
MRF 3 or 4 13 70 1.30 (0.65, 2.60) 75 364 1.14 (0.69, 1.90) 
MRF 2 50 351 1.41 (0.90, 2.20) 175 777 0.99 (0.68, 1.44) 
MRF 1 81 816 1.04 (0.75, 1.43) 165 758 0.92 (0.64, 1.32) 
MRF 0 159 1733 Referent 65 262 Referent 
Missing 68 803  100 
492  
 
Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor. 
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 6: Association between Individual Metabolic Risk Factors and Breast Cancer Risk among Females 
 
                                All women (n = 6339, Cancer cases = 236) 
Postmenopausal women  
(n =2954, Cancer cases =124) 
Variable Cancer cases Sample size 
Hazard ratio
a 
 
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
 
(95% CI) 
BMI≥30 50 1212 0.81 (0.51, 1.31) 33  700  0.80 (0.43, 1.50)  
BMI<30 186 5127 Referent 91  2254  Referent 
 High BP 107 2612 1.19 (0.81, 1.73) 83  1847  1.70 (1.001, 2.88)  
< High BP 129 3727 Referent 41  1107  Referent 
Cholesterol≥240 89 2044 1.13 (0.78, 1.63) 66  1487  1.16 (0.75, 1.79)  
Cholesterol<240 147 4295 Referent 58  1467  Referent 
Diabetes 14 306 1.63 (0.81, 3.29) 13  245  2.32 (1.09, 4.95)  
No Diabetes 177 4825 Referent 83  2171  Referent 
Missing 45 1208  
28  538   
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 7: Association between Combined Metabolic Risk Factors Score and Breast Cancer Risk among Females 
 
                        All women 
                           (n = 6426, Cancer cases = 239) 
Postmenopausal women  
(n = 2998, Cancer cases = 126) 
Variable Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
MRF 3 or 4 21 434 1.44 (0.68, 3.04) 19  365  3.26 (1.23, 8.65)  
MRF 2 46 1128 1.09 (0.62, 1.92) 34  819  2.16 (0.89, 5.22)  
MRF 1 56 1574 0.93 (0.57, 1.52) 30  837  1.53 (0.64, 3.62)  
MRF 0 68 1995 Referent 13  395  Referent 
Missing 48 1295 
 30  
582   
 
Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor. 
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 8: Association between Individual Metabolic Risk Factors and Digestive Cancer Risk by Gender 
 
Males (n = 4355, Cancer cases = 196) Females (n = 6339, Cancer cases = 207) 
Variable Cancer cases Sample size 
Hazard ratio
a 
 
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
 
(95% CI) 
BMI≥30 36 567 1.92 (1.15, 3.21) 52 1212 0.86 (0.58, 1.29) 
BMI<30 160 3788 Referent 155 5127 Referent 
 High BP 116 2239 1.02 (0.65, 1.59) 132 2612 1.36 (0.93, 1.99) 
< High BP 80 2116 Referent 75 3727 Referent 
Cholesterol≥240 57 1339 0.90 (0.58, 1.38) 107 2044 1.32 (0.93, 1.87) 
Cholesterol<240 139 3016 Referent 100 4295 Referent 
Diabetes 9 212 1.47 (0.54, 4.01) 13 306 0.89 (0.36, 2.17) 
No Diabetes 148 3144 Referent 168 4825 Referent 
Missing 39 999 
 
26 1208  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 9: Association between Combined Metabolic Risk Factors and Digestive Cancer Risk by Gender 
 
Males (n = 4383, Cancer cases = 196) Females (n = 6426, Cancer cases = 211) 
Variable Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
MRF 3 or 4 7 173 1.32 (0.42, 4.16) 28 434 1.05 (0.54, 2.05) 
MRF 2 43 796 1.32 (0.66, 2.65) 67 1128 0.98 (0.58, 1.65) 
MRF 1 69 1351 1.35 (0.71, 2.56) 44 1574 0.49 (0.26, 0.91) 
MRF 0 38 1036 Referent 42 1995 Referent 
Missing 39 1027  30 
1295  
 
Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor. 
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 10: Association between Individual Metabolic Risk Factors and Lung Cancer Risk by Gender 
 
Males (n = 4355, Cancer cases = 174) Females (n = 6339, Cancer cases = 81) 
Variable Cancer cases Sample size 
Hazard ratio
a 
 
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
 
(95% CI) 
BMI≥30 20 567 0.97 (0.48, 1.95) 15 1212 0.85 (0.38, 1.91) 
BMI<30 154 3788 Referent 66 5127 Referent 
 High BP 86 2239 0.86 (0.60, 1.24) 39 2612 0.62 (0.33, 1.14) 
< High BP 88 2116 Referent 42 3727 Referent 
Cholesterol≥240 56 1339 1.22 (0.85, 1.75) 38 2044 1.51 (0.80, 2.84) 
Cholesterol<240 118 3016 Referent 43 4295 Referent 
Diabetes 9 212 1.14 (0.45, 2.87) 6 306 1.70 (0.52, 5.56) 
No Diabetes 131 3144 Referent 58 4825 Referent 
Missing 34 999 
 
17 1208  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 11: Association between Combined Metabolic Risk Factors and Lung Cancer Risk by Gender 
 
Males (n = 4383, Cancer cases = 175) Females (n = 6426, Cancer cases = 83) 
Variable Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
Cancer cases Sample size 
Hazard ratio
a
  
(95% CI) 
MRF 3 or 4 5 173 1.05 (0.25, 4.46) 6 434 0.66 (0.14, 3.09) 
MRF 2 30 796 0.93 (0.51, 1.68) 20 1128 0.76 (0.31, 1.84) 
MRF 1 65 1351 1.22 (0.66, 2.26) 20 1574 0.63 (0.26, 1.57) 
MRF 0 40 1036 Referent 18 1995 Referent 
Missing 35 1027  19 
1295  
 
Abbreviations: CI, Confidence Interval; MRF, Metabolic Risk Factor.  
a
 Hazard ratios were adjusted for age (years, continuous), race (White, others), education (high school or less, college), family 
income (<$5,000, $5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or 
missing data), family history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Appendix C: Association between metabolic risk factors and age at cancer onset 
Table 1. Characteristics of the Study Population, National Health and Nutrition 
Examination Survey I  (NHANES I) Epidemiologic Follow-up Study, 1971-1992 
(Unweighted sample size = 1,736 ) 
  
Characteristics of the study population Frequency % Mean (SE) 
Age at baseline (years)   56.4 (0.31) 
Age at cancer (years)   67.9 (0.31) 
Women 914 52.6  
Men 822 47.4  
Race/ethnicity    
    White 1502 86.5  
    Non-white 234 13.5  
Family income    
    Below $5,000 543 31.3  
    $5,001 - $15,000 864 49.8  
    Above $15,000 329 19.0  
Education    
    High school or less 1400 80.6  
    Above high school 336 19.4  
Physical activity    
    Moderately or very active 1559 89.8  
    Quite inactive 177 10.2  
Smoked 100 cigarettes in lifetime    
Yes 984 56.7  
No 673 38.8  
Missing 79 4.6  
Family history of cancer    
Yes 707 40.7  
No  845 48.7  
Missing 184 10.6  
BMI,  kg/m
2
   26.0 (0.12) 
BMI categories    
    Underweight 31 1.8  
    Healthy weight 765 44.1  
    Overweight 641 36.9  
    Obese 299 17.2  
Blood pressure (mmHg)     
Diastolic   84.3 (0.31) 
Systolic   137.7 (0.57) 
    High BP 902 52.0  
    No high BP  834 48.0  
                  Continued...  
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Serum cholesterol (mg/dL)   228.7 (1.23) 
    High (>=240 mg/dL) 668 38.5  
Low (< 240 mg/dL) 1068 61.5  
Diabetes    
Yes 84 4.8  
No 1334 76.8  
Missing 318 18.3  
Metabolic Risk Factor (MRF)    
     MRF 0 400 23.0  
     MRF 1 522 30.1  
     MRF 2 383 22.1  
     MRF 3 or 4 113 6.5  
Missing 335 19.3  
 
Abbreviations: BMI, Body mass index; SE, Standard error.
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Appendix C 
 
Table 2: Association between Individual Metabolic Risk Factors and Age at Cancer Onset among Males 
 
 
Age <50 Years (n= 140) Age ≥ 50 Years (n = 682) 
Variable Cancer cases 
Mean difference
a 
 
(95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
BMI≥30 kg/m2 18 2.71 (0.96, 4.47) 87 0.27 (-0.99, 1.53) 
BMI<30 kg/m
2
 122 Referent 595 Referent 
 High BP 56 1.47 (-0.25, 3.20) 391 0.04 (-0.96, 1.05) 
< High BP 84 Referent 291 Referent 
Cholesterol≥240 mg/dL 44 -1.47 (-3.45, 0.51) 230 0.45 (-0.39, 1.30) 
Cholesterol<240 mg/dL 96 Referent 452 Referent 
Diabetes 4 -4.36 (-7.77, -0.96) 33 -2.78 (-5.34, -0.22) 
No Diabetes 102 Referent 517 Referent 
Missing 34 
 
132  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 3: Association between Individual Metabolic Risk Factors and Age at Cancer Onset among Females 
 
 
Age <50 Years (n = 362) Age ≥ 50 Years (n = 552) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
BMI≥30 kg/m2 69 -0.80 (-2.39, 0.79) 125 -0.89 (-2.29, 0.51)  
BMI<30 kg/m
2
 293 Referent 427 Referent 
 High BP 96 1.25 (-0.10, 2.61) 359 -0.05 (-1.13, 1.02) 
< High BP 266 Referent 193 Referent 
Cholesterol≥240 mg/dL 83 0.32 (-0.77, 1.41) 311 -0.20 (-1.12, 0.72) 
Cholesterol<240 mg/dL 279 Referent 241 Referent 
Diabetes 9 -0.20 (-3.47, 3.08) 38 -1.97 (-3.72, -0.21) 
No Diabetes 292 Referent 423 Referent 
Missing 61 
 
91  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 4: Association between Combined Metabolic Risk Factors and Age at Cancer Onset among Males 
 
 
Age <50 Years (n = 141) Age ≥ 50 Years (n = 683) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
MRF 3 or 4 5 2.65 (-0.79, 6.10) 22 0.73 (-2.36, 3.82) 
MRF 2 21 0.90 (-2.50, 4.30) 146 0.13 (-1.35, 1.61) 
MRF 1 37 -0.18 (-2.30, 1.95) 247 -0.40 (-1.71, 0.92) 
MRF 0 43 Referent 135 Referent 
Missing 35 
 
133  
 
Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor. 
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 5: Association between Combined Metabolic Risk Factors and Age at Cancer Onset among Females 
 
 
Age <50 Years (n = 369) Age ≥ 50 Years (n = 560) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
MRF 3 or 4 13 2.78 (0.41, 5.14) 73 -2.64 (-4.60, -0.68) 
MRF 2 50 0.48 (-1.08, 2.05) 166 0.29 (-1.62, 2.20) 
MRF 1 79 -0.77 (-2.38, 0.85) 159 -0.25 (-2.05, 1.55) 
MRF 0 159 Referent 63 Referent 
Missing 68 
 
99  
 
Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 6: Association between Individual Metabolic Risk Factors and Age at Breast Cancer Onset among Females 
 
 
All women (n = 223) Postmenopausal women (n = 112) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
BMI≥30 kg/m2 48 -1.78 (-3.78, 0.23) 31  -0.37 (-2.64, 1.90)  
BMI<30 kg/m
2
 181 Referent 81  Referent 
 High BP 101 1.02 (-0.96, 3.00) 75  0.10 (-2.30, 2.50)  
< High BP 128 Referent 37  Referent 
Cholesterol≥240 mg/dL 88 -0.60 (-2.53, 1.33) 60  -0.93 (-3.30, 1.43)  
Cholesterol<240 mg/dL 141 Referent 52  Referent 
Diabetes 14 -2.78 (-5.82, 0.25) 13  -2.61 (-4.89, -0.33)  
No Diabetes 169 Referent 72  Referent 
Missing 46 
 
27   
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 7: Association between Combined Metabolic Risk Factors and Age at Breast Cancer Onset among Females 
 
 
All women (n = 226) Postmenopausal women (n = 114) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
MRF 3 or 4 21 -3.31 (-6.12, -0.50) 19  -3.84 (-6.71, -0.96)  
MRF 2 44 -0.98 (-4.08, 2.13) 29  -2.55 (-6.31, 1.20)  
MRF 1 51 -2.13 (-4.27, 0.01) 26  -2.46 (-5.41, 0.48)  
MRF 0 67 Referent 11  Referent 
Missing 50 
 
29   
 
Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Table 8: Association between Individual Metabolic Risk Factors and Age at Digestive Cancer Onset by Gender 
 
 
Males (n = 194) Females (n = 203) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
BMI≥30 kg/m2 34 0.17 (-2.01, 2.36) 51 -1.66 (-3.45, 0.13) 
BMI<30 kg/m
2
 160 Referent 152 Referent 
 High BP 114 0.79 (-1.08, 2.66) 128 -1.03 (-2.80, 0.75) 
< High BP 80 Referent 75 Referent 
Cholesterol≥240 mg/dL 57 0.34 (-1.53, 2.22) 104 0.17 (-1.75, 2.08) 
Cholesterol<240 mg/dL 137 Referent 99 Referent 
Diabetes 9 -0.21 (-3.04, 2.62) 13 -2.21 (-4.88, 0.46) 
No Diabetes 147 Referent 164 Referent 
Missing 38 
 
26  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Appendix C 
 
Table 9: Association between Combined Metabolic Risk Factors and Age at Digestive Cancer Onset by Gender 
 
 
Males (n = 194) Females (n = 207) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
MRF 3 or 4 7 0.98 (-2.26, 4.22) 27 -4.42 (-6.63, -2.22) 
MRF 2 42 1.04 (-1.73, 3.82) 65 -1.35 (-3.64, 0.95) 
MRF 1 69 -0.67 (-2.83, 1.50) 43 -3.09 (-5.41, -0.77) 
MRF 0 38 Referent 42 Referent 
Missing 38 
 
30  
 
Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Appendix C 
 
Table 10: Association between Individual Metabolic Risk Factors and Age at Lung Cancer Onset by Gender 
 
 
Males (n = 174) Females (n = 80) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
BMI≥30 kg/m2 20 -0.44 (-2.78, 1.91) 15 1.34 (-0.73, 3.40) 
BMI<30 kg/m
2
 154 Referent 65 Referent 
 High BP 86 0.66 (-1.02, 2.34) 38 1.07 (-0.90, 3.04) 
< High BP 88 Referent 42 Referent 
Cholesterol≥240 mg/dL 56 0.29 (-1.60, 2.17) 37 0.46 (-1.71, 2.62) 
Cholesterol<240 mg/dL 118 Referent 43 Referent 
Diabetes 9 -7.40 (-10.37, -4.43) 6 -4.59 (-8.18, -1.01) 
No Diabetes 131 Referent 57 Referent 
Missing 34 
 
17  
 
Abbreviations: BMI, Body Mass Index; BP, Blood Pressure; CI, Confidence Interval.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
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Appendix C 
 
Table 11: Association between Combined Metabolic Risk Factors and Age at Lung Cancer Onset by Gender 
 
 
Males (n = 175) Females (n = 82) 
Variable Cancer cases 
Mean difference
a 
 
 (95% CI) 
Cancer cases 
Mean difference
a 
 
 (95% CI) 
MRF 3 or 4 5 -3.76 (-6.63, -0.88) 6 -2.92 (-8.93, 3.10) 
MRF 2 30 0.44 (-2.44, 3.32) 19 -0.05 (-3.53, 3.44) 
MRF 1 65 -1.36 (-3.53, 0.82) 20 -0.87 (-4.00, 2.25) 
MRF 0 40 Referent 18 Referent 
Missing 35 
 19 
 
 
Abbreviations: CI, Confidence Interval, MRF, Metabolic Risk Factor.  
a
Adjusted for age (years, continuous), race (White, others), education (high school or less, college), family income (<$5,000, 
$5,000 to <$15,000, and >=$15,000), smoking status (smoked 100 cigarettes in one's lifetime, yes, no or missing data), family 
history of cancer (yes, no or missing data), and physical activity (moderately or very active, quite inactive). 
 
